---
document_datetime: 2023-09-21 20:15:35
document_pages: 53
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/epclusa-h-c-4210-x-43-g-epar-assessment-report-variation_en.pdf
document_name: epclusa-h-c-4210-x-43-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 57.3325598
conversion_datetime: 2025-12-23 01:24:59.376732
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 June 2020 EMA/379603/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Epclusa

International non-proprietary name: sofosbuvir / velpatasvir

Procedure No. EMEA/H/C/004210/X/0043/G

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                 | 7                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................7    |                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                       | ........................................................7                                                |
| 2. Scientific discussion................................................................................                 | 8                                                                                                        |
| 2.1. Problem statement...............................................................................................8   |                                                                                                          |
| 2.1.1. Disease or condition                                                                                              | ..........................................................................................8              |
| 2.1.2. About the product ...........................................................................................     | 10                                                                                                       |
| 2.2. Quality aspects                                                                                                     | .................................................................................................. 10    |
| 2.2.1. Introduction....................................................................................................  | 10                                                                                                       |
| 2.2.2. Active Substance - Sofosbuvir, Velpatasvir.........................................................               | 10                                                                                                       |
| 2.2.3. Finished Medicinal Product................................................................................        | 11                                                                                                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                       | 14                                                                                                       |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                | ...................... 14                                                                                |
| 2.2.6. Recommendations for future quality development                                                                    | ............................................... 14                                                       |
| 2.3. Non-clinical aspects............................................................................................    | 14                                                                                                       |
| 2.3.1. Ecotoxicity/environmental risk assessment                                                                         | ................................................ 14                                                      |
| 2.3.2. Discussion and conclusion on non-clinical aspects                                                                 | ...................................... 15                                                                |
| 2.4. Clinical aspects .................................................................................................. | 16                                                                                                       |
| 2.4.1. Introduction....................................................................................................  | 16                                                                                                       |
| 2.4.2. Clinical pharmacology                                                                                             | ...................................................................................... 17                |
| 2.4.3. Discussion on clinical pharmacology...................................................................            | 29                                                                                                       |
| 2.4.4. Conclusions on clinical pharmacology.................................................................             | 30                                                                                                       |
| 2.5. Clinical efficacy                                                                                                   | .................................................................................................. 31    |
| 2.5.1. Main study                                                                                                        | ..................................................................................................... 31 |
| 2.5.2. Discussion on clinical efficacy............................................................................       | 34                                                                                                       |
| 2.5.3. Conclusions on the clinical efficacy                                                                              | .................................................................... 35                                  |
| 2.6. Clinical safety                                                                                                     | .................................................................................................... 36  |
| 2.6.1. Patient exposure                                                                                                  | ............................................................................................. 36         |
| 2.6.2. Adverse events                                                                                                    | ............................................................................................... 36       |
| 2.6.3. Serious adverse event/deaths/other significant events.........................................                    | 37                                                                                                       |
| 2.6.4. Laboratory findings..........................................................................................     | 41                                                                                                       |
| 2.6.5. Discussion on clinical safety..............................................................................       | 43                                                                                                       |
| 2.6.6. Conclusions on the clinical safety                                                                                | ...................................................................... 43                                |
| 2.7. Risk Management Plan........................................................................................        | 43                                                                                                       |
| 2.8. Pharmacovigilance                                                                                                   | ............................................................................................. 48         |
| 2.9. Product information............................................................................................     | 49                                                                                                       |
| 2.9.1. User consultation                                                                                                 | ............................................................................................ 49          |
| 2.9.2. Additional monitoring.......................................................................................      | 49                                                                                                       |
| 3.1. Therapeutic Context                                                                                                 | ........................................................................................... 49           |

<div style=\"page-break-after: always\"></div>

3.1.1. Disease or condition ........................................................................................  49

3.1.2. Available therapies and unmet medical need  ....................................................... 49

3.1.3. Main clinical studies  .........................................................................................  49

3.2. Favourable effects  ..............................................................................................  50

3.3. Uncertainties and limitations about favourable effects  ............................................. 50

3.4. Unfavourable effects  ...........................................................................................  50

3.5. Uncertainties and limitations about unfavourable effects ......................................... 50

3.6. Benefit-risk assessment and discussion  ................................................................. 51

3.6.1. Importance of favourable and unfavourable effects  .............................................. 51

3.6.2. Balance of benefits and risks ............................................................................  51

3.7. Conclusions  .......................................................................................................  51

4. Recommendations  ................................................................................. 51

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

adverse event

ALT

alanine aminotransferase

AS

active substance

AUC

area under the concentration versus time curve

AUCinf

area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/ λ z)

AUClast

area under the concentration versus time curve from time zero to the last quantifiable concentration

AUCtau

area under the concentration versus time curve over the dosing interval Bioavailability

BA

BCS

Biopharmaceutics Classification System

BMI

body mass index

CFR

Code of Federal Regulations

CHMP

Committee for Medicinal Products for Human use

CI

confidence interval

CLCRSW

creatinine clearance estimated by the Schwartz formula

Cmax

maximum observed concentration of drug

CoA

Certificate of Analysis

CQA

Critical quality attribute

CSR

clinical study report

DAA

direct-acting antiviral

EC

European Commission

eGFR

estimated glomerular filtration rate

EMEA

European Medicines Evaluation Agency

EU

European Union

FDA

Food and Drug Administration

FDC

fixed-dose combination

GC

Gas chromatography

GCP

Good Clinical Practice

Gilead

Gilead Sciences

HCC

hepatocellular carcinoma

HCV

hepatitis C virus

HDPE

High Density Polyethylene

HPLC

High performance liquid chromatography

ICH

International Council for Harmonisation (of Technical Requirements for Pharmaceuticals for Human Use)

IFN

Interferon

IL28B

IL28B gene

IND

investigational new drug (application)

IPC

In-process control

LDV

Ledipasvir

LDV-SDD

Ledipasvir spray-dried dispersion

LDV/SOF

ledipasvir/sofosbuvir (coformulated; Harvoni)

LLOQ

lower limit of quantitation

MAH

Marketing Authorisation holder

N or n

number of subjects in a population (N) or subset (n)

NA

not applicable

NDA

new drug application

NF

National formulary

NI

nucleoside inhibitor

NS (3/4A/5A/5B)

nonstructural protein (3/4A/5A/5B)

PAR

Proven acceptable range

PBRER

Periodic Benefit-Risk Evaluation Report

pcVPC

PDCO

Prediction corrected visual predictive check

Paediatric Development Committee

PDE

Permitted Daily Exposure

PE

Polyethylene

Peg-IFN

pegylated interferon

PET

Polyethylene terephthalate

Ph. Eur.

European Pharmacopoeia

PIP

paediatric investigation plan

PK

pharmacokinetic(s)

PREA

Paediatric Research Equity Act

PSUR

Periodic Safety Update Report

QbD

Quality by design

QC

Quality control

RAV

resistance-associated variant

RBV

Ribavirin

RH

Relative humidity

RNA

ribonucleic acid

rpm

Revolutions per minute

SAE

serious adverse event

SD

standard deviation

SDD

spray-dried dispersion

SLS

Sodium lauryl sulfate

SmPC

Summary of product characteristics

SOF

SOF/VEL

sofosbuvir (Sovaldi)

sofosbuvir/velpatasvir (Epclusa)

SVR, SVRxx

sustained virologic response, sustained virologic response at 'xx' weeks following completion of all treatment

TSE

Transmissible spongiform encephalopathy

uHPLC

ultra-high performance liquid chromatography

UK

United Kingdom

ULN

upper limit of normal

US, USA

United States, United States of America

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| USP   | United States Pharmacopoeia   |
|-------|-------------------------------|
| UV    | Ultraviolet                   |
| VEL   | Velpatasvir                   |
| WHO   | World Health Organization     |
| WR    | Written Request               |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Gilead Sciences Ireland UC submitted on 14 October 2019 a group of variation(s) consisting of an extension of the marketing authorisation and the following variation(s):

| Variation(s) requested   | Variation(s) requested                                                                                                         | Type   |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                  | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Extension application to introduce a new strength (200/50 mg film-coated tablets). The new presentation is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 6 years and older.

The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 6 to &lt; 18 years to the existing strength of 400/100 mg film-coated tablets. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.1) is updated in accordance.

In addition, the MAH took the opportunity to implement minor editorial updates throughout the Product Information.

## The legal basis for this application refers to:

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## Information on Paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Filip Josephson

Co-Rapporteur:  N/A

CHMP Peer reviewer(s): N/A

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                              | 14 October 2019   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                                | 31 October 2019   |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                          | 21 January 2020   |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                     | 28 January 2020   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 13 February 2020  |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                       | 27 February 2020  |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                           | 23 April 2020     |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                 | 26 May 2020       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 11 June 2020      |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Epclusa on | 25 June 2020      |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

## 2.1.1.1. Epidemiology

Hepatitis C virus infection is a global health challenge with an estimated global prevalence of 1%, for a total of 71 million individuals worldwide chronically infected with HCV (The Polaris Observatory HCV Collaborators 2017), (World Health Organization (WHO) 2018b). In the US, over 3 million people are estimated to be chronically infected with HCV (Center for Disease Control and Prevention 2016), and in Europe an estimated

<div style=\"page-break-after: always\"></div>

10 to 14 million people have chronic HCV infection (The Polaris Observatory HCV Collaborators 2017), (World Health Organization (WHO) 2018c). Up to 85% of individuals infected with HCV fail to clear the virus and progress to chronic infection; over the ensuing 20 years, as many as 20% of patients with chronic HCV infection are estimated to develop complications, including cirrhosis, end stage liver disease, and hepatocellular carcinoma (HCC). Curing HCV infection is associated with numerous health benefits, including more than 70% reduction in the risk of HCC and 90% reduction in the risk of liver-related mortality and liver transplantation (Morgan 2013), (van der Meer 2012), (Veldt 2007), (Poynard 2002).

The estimated prevalence of HCV infection in children is up to 0.4% in Europe and the US and up to 6% in resource-limited countries (El-Shabrawi 2013), (Khaderi 2014). Globally, it is estimated that approximately 2.1 to 3.5 million individuals 15 years of age or younger are chronically infected with HCV (Nwaohiri 2018), (European Association for the Study of the Liver (EASL) 2018).

## 2.1.1.2. Aetiology and pathogenesis

The primary mechanism of HCV infection in children is vertical transmission, with parenteral transmission secondary. Following vertical transmission of HCV, in the absence of treatment, approximately 20% to 40% of children clear the infection spontaneously, usually in the first 4 to 7 years of life, whereas the remaining 60% to 80% develop chronic infection that persists into adulthood (Mack 2012), (Indolfi 2018).

## 2.1.1.3. Clinical presentation

The natural history of chronic HCV infection in children is generally similar to that in adults, although HCV infection in children is typically relatively mild (Squires 2017). Most children chronically infected with HCV are asymptomatic or have mild, nonspecific symptoms. Clinical symptoms are present in approximately 20% of children in the first 4 years of life, with hepatomegaly being the most frequent sign (10%). Many, but not all, perinatally-infected children will have intermittently or persistently abnormal alanine aminotransferase (ALT) or aspartate aminotransferase levels, particularly in the first 2 years of life. In children with vertical HCV infection who have undergone liver biopsy, the histological spectrum is usually mild, although severe liver disease is encountered {Mohan 2010}. Despite the overall more favourable prognosis compared with adults, approximately 4% to 6% of children with chronic HCV infection have evidence of advanced fibrosis or cirrhosis and some children eventually require liver transplantation as a consequence of HCV infection (Hu 2010), (Wirth 2012). In addition, HCV infection has been reported to negatively affect both the health-related quality of life and cognitive functioning of paediatric patients (Nydegger 2008), (Rodrigue 2009), (Abu Faddan 2015), (Annunziato 2017).

## 2.1.1.4. Management

The goal of HCV treatment in both paediatric and adult populations is viral eradication, thereby preventing progressive hepatic inflammation, hepatic fibrosis, cirrhosis, and liver failure that result in the need for liver transplantation. Over the past 7 years, the development and approval of safe and effective direct-acting antivirals (DAAs) have transformed the treatment and course of HCV infection in adults. Several DAA therapies containing sofosbuvir have been approved for the treatment of adults with chronic HCV infection (Sovaldi, Harvoni, Epclusa and Vosevi).

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

Epclusa was approved in 2016 for the treatment of chronic hepatitis C in adults.  It is a fixed dose combination of sofosbuvir, an HCV polymerase inhibitor, and velpatasvir, an NS5A-inhibitor.  It is pangenotypic, indicated regardless of HCV genotype.

## Type of Application and aspects on development

In the EU, a paediatric investigation plan (PIP) for SOF/VEL was agreed on 08 May 2015 (EMEA-001646PIP01-14). Minor modifications to the original PIP have been agreed since that time, most recently on 18 May 2018 (EMEA-001646-PIP01-14-M02). The design of GS-US-342-1143 reflected the PIP Decision agreed with the Paediatric Development Committee (PDCO) as part of the assessment of the PIP.

## 2.2. Quality aspects

## 2.2.1. Introduction

This application is a line extension to the already approved Epclusa 400 mg/100 mg film-coated tablets. This line extension involves the addition of a 200/50 mg strength film-coated tablets and an extension of indication.

The finished product is presented as film-coated tablets containing 200 mg sofosbuvir and 50 mg velpatasvir as active substances.

Other ingredients are:

Tablet core: copovidone, microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Film-coating: polyvinyl alcohol, titanium dioxide (E171), polyethylene glycol, talc and iron oxide red (E172).

The product is available in high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure containing 28 film-coated tablets with polyester coil as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance - Sofosbuvir, Velpatasvir

## General information

This application is a line extension and contains the same active substances, sofosbuvir and velpatasvir, used to manufacture the already-approved film-coated tablets. The information presented by the Applicant in the dossier was already assessed in the original submission and includes updates from any subsequent variations. The active substances are sourced from the same manufacturers, are manufactured by the same processes and are released in accordance with the same active substance specifications.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Epclusa 200 mg/50 mg film-coated tablets are pink, oval-shaped, film-coated tablets of dimensions 14 x 7 mm, debossed on one side with 'GSI' and 'S/V' on the other side.

The aim of development was to identify a lower strength solid oral dosage form for use in paediatric patients. Development was based on the already approved 400/100 mg film-coated tablets, including the use of the same manufacturing process, adapted to the smaller tablet size, utilizing the identical formulation composition that is dose-proportional. Subsequent to the commercialization of the 400/100 mg strength, the reduced-strength 200/50 mg tablet was developed for use by paediatric patients unable to swallow a larger tablet. The 200/50 mg tablet was used to support Phase 2 paediatric studies and primary stability studies.

The qualitative composition of the 200/50 mg film-coated tablets and existing Epclusa 400/100 mg filmcoated tablets is identical. The quantitative composition for the 200/50 mg film-coated tablets is proportional to the existing Epclusa 400/100 mg film-coated tablets for all the components. The dose strengths can be differentiated by different sizes, shape and dimensions.

The active substances are the same as those used in the approved higher strength tablets. Velpatasvir free base is a stable amorphous solid, no stable crystalline forms have been isolated. It exhibits pH-dependent solubility over the physiological pH range of 2 to 8. Velpatasvir solubility increases with decreasing pH. Velpatasvir is considered to have low solubility and low apparent intestinal permeability based on low oral bioavailability (BCS class IV).

Sofosbuvir is a crystalline solid, routinely manufactured as the most stable polymorphic form containing small quantities of an equivalent polymorphic form. Sofosbuvir exhibits pH-independent solubility across the physiological pH range. Sofosbuvir is highly soluble but has low apparent intestinal permeability (BCS class III).

The excipients used in the 200/50 mg film-coated tablets are the same as those used in the 400/100 mg film-coated tablets and their compatibility with the active substance was demonstrated in stability studies. They are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. Standards, except for the film-coating material, Opadry II Pink tested according to an in-house standard. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

The dissolution method is the same as used for the already-approved 400/100 mg film-coated tablets.

The existing 400 mg/100 mg tablets and 200 mg/50 mg tablets are both manufactured using the same manufacturing process train. The manufacturing process for VEL SDD was assessed in connection with the approval of Epclusa tablets, 400 mg/100 mg. No new information is provided in this application and no further assessment is made at this stage.

The manufacturing process for the 200 mg/50 mg tablets was developed and optimized at the proposed manufacturing site. The development and optimization of the manufacturing process involved a tablet compression study and a film-coating study to define the commercial process parameters. The results of these studies were used to establish proposed targets and PARs for the commercial process. For the drying and dry granulation steps, the manufacturing processes and associated operating parameters were within the ranges defined in the current SOF/VEL tablet, 400 mg/100 mg, process and no additional work was

<div style=\"page-break-after: always\"></div>

conducted. A confirmation study was performed to verify the suitability of the dry granulation process parameter ranges for the SOF/VEL tablet, 200 mg/50 mg. The parameter ranges used in these studies are considered as PARs and were summarized in the dossier.

The primary packaging is HDPE bottle and a polypropylene (PP) continuous thread child-resistant cap lined with an induction activated aluminium foil liner. The materials comply with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturing process consists of two parts: manufacture of velpatasvir spray-dried dispersion (VELSDD) and then production of the film-coated tablets.

The first part of the manufacturing process (manufacture of VEL-SDD) consists of four main steps: feed solution preparation, drying, secondary drying, and packaging of VEL SDD.

The manufacturing process for the VEL-SDD is identical to that used for the approved 400/100 mg filmcoated tablets. The controls applied to the VEL-SDD intermediate have previously been assessed in the context of the original MAA and are considered appropriate.

The tablet manufacturing process consists of three main steps: (1) powder processing (dispensing, blending, and dry granulation), (2) tablet compression, and (3) film-coating of tablet cores to yield film-coated tablets. IPCs are carried out to monitor the critical steps of the manufacturing process. The IPCs are adequate for this type of manufacturing process and pharmaceutical form.

Major steps of the manufacturing process have been validated by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this film-coated tablet manufacturing process.

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form: appearance, identity (UPLC, UV), water content (Ph. Eur., USP), assay (UPLC), degradation products (UPLC), uniformity of dosage units (Ph. Eur., USP), dissolution (Ph. Eur., USP) and microbiological enumeration (Ph. Eur., USP).

The specification for the 200 mg/50 mg tablets utilizes the same tests and acceptance limits as approved for Epclusa film-coated tablets, 400 mg/100 mg. The proposed specification is considered acceptable.

The potential presence of class 1, 2A and selected class 3 elemental impurities in the finished product has been assessed on a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on seven representative pilot scale batches and three primary stability batches using a validated method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

<div style=\"page-break-after: always\"></div>

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

The finished product is released onto the market based on the above release specifications, through traditional final product release testing.

A risk assessment concerning the presence of nitrosamine impurities was performed for the finished product based on the combined recommendations from health authorities, including EMA communication EMA/189634/2019; it was concluded that there is no risk related to the presence of nitrosamine impurities in the product. Therefore, no changes to the control strategy for Epclusa are necessary to mitigate potential contamination by nitrosamines. The nitrosamine impurities risk assessment of the finished product included evaluating contributions from sofosbuvir and velpatasvir active substances, VEL spray-dried dispersion, excipients, finished product manufacturing facilities, and packaging components.

Batch analysis results are provided for four production scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability data from 3 production scale batches 200/50 mg film-coated tablets stored for up to 6 months under long term conditions (30 ºC / 75% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing. Samples were tested for appearance, water content, assay, degradation products, dissolution, total aerobic microbial count, total combined yeasts and moulds count, and Escherichia coli . No significant changes were observed to any of the measured parameters under any conditions and the results were comparable to the data from the approved 400/100 mg film-coated tablets at each time-point.

A further consideration is that the already-marketed 400/100 mg film-coated tablets have a 48-month shelflife based on extensive stability data which revealed little or no change in any of the measured quality attributes, and that the two strengths of tablet are manufactured from a common blend. Photostability data was generated for the 400/100 mg film-coated tablets indicating that Epclusa film-coated tablets are not photosensitive. Additional stability data reveals that the product is not impacted by freezing or temporary exposure to high temperature (60 ºC), which means that temperature excursions outside the normal temperature range which may be encountered during shipping will not have an adverse effect on product quality.

Based on available stability data, the proposed shelf-life of 4 years without any special storage conditions as stated in the SmPC (section 6.3) is acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. Satisfactory information has been provided in regard of the new presentation intended for treatment of paediatric patients. The applicant has applied QbD principles in the development of the finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the active substance, nor for the finished product.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of the 200mg/50mg film-coated tablet is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendations for future quality development

Not applicable.

## 2.3. Non-clinical aspects

No new non-clinical studies have been submitted for this procedure.

## 2.3.1. Ecotoxicity/environmental risk assessment

Regarding the ecotoxicological aspects of Epclusa, the environmental risk assessment (ERA) for SOF has been conducted for its major metabolite (GS-331007) with the conclusion that the use of SOF is not expected to pose a risk to the environment.

No conclusion on the environmental risk of VEL was made for Epclusa as VEL has been found to be persistent in sediments and there was data missing on the potential for bioaccumulation in sediment-dwelling organisms. This was to some extent resolved with a study on bioaccumulation in sediment-dwelling benthic oligochaetes (OECD TG315, a study with adult Lumbriculus variegatus that is considered to provide indications of bioaccumulation potential) in procedure EMEA/H/C/004210/IB/0013. The outcome was a normalized BAF of 0.122, indicating that VEL is rapidly eliminated and has very little potential for bioaccumulation in sediment-dwellers. That being said, as no definite equilibrium or kinetic bioaccumulation factor (BAFss; BAFk) could be determined in the study and as there are (at the present time) no formal criteria for bioaccumulation for OECD TG315 data, some uncertainty remains.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Discussion and conclusion on non-clinical aspects

No new non-clinical studies have been submitted for this procedure. This is in line with the agreed paediatric investigation plan for sofosbuvir / velpatasvir (SOF/VEL, product name Epclusa), (EMEA-01646-PIP01-14M02) and therefore acceptable.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

## Table 1 Clinical Study Included in the Update to the SOF/VEL Marketing Application for Paediatric Subjects (6 to &lt; 18 years old)

| Study Number     | Study Design                                   | Subject Population                                                                                 | Treatment Regimen b   | N c                                                                                                                      |
|------------------|------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------|
| GS-US-342-1143 a | Phase 2, open-label, multicohort, 2-part study | Treatment-naive and treatment- experienced subjects 3 to < 18 years old with chronic HCV infection | SOF/VEL for 12 weeks  | 12 to < 18 years: 102 Genotype 1: 75 Genotype 2: 6 Genotype 3: 12 Genotype 4: 2 Genotype 5: 0 Genotype 6: 6 Missing: 1 d |
| GS-US-342-1143 a | Phase 2, open-label, multicohort, 2-part study | Treatment-naive and treatment- experienced subjects 3 to < 18 years old with chronic HCV infection | SOF/VEL for 12 weeks  | 6 to < 12 years: 73 e Genotype 1: 56 Genotype 2: 2 Genotype 3: 11 Genotype 4: 4 Genotype 5: 0 Genotype 6: 0              |

- a Only data for subjects 12 to &lt; 18 years old and 6 to &lt; 12 years old are discussed in this summary.
- b The doses and formulations of SOF/VEL were based on age group as follows:
- Adolescent subjects 12 to &lt; 18 years old received SOF/VEL 400/100 mg orally, once daily (1 × 400/100-mg tablet or 2 × 200/50-mg tablets).
- Pediatric subjects 6 to &lt; 12 years old received SOF/VEL 200/50 mg orally, once daily (1 × 200/50-mg tablet or 4 × 50/12.5-mg packets containing granules).

The selection of SOF/VEL formulation was based on a swallowability assessment using a placebo tablet at baseline.

- c N = Number of subjects in the Safety Analysis Set, which included all subjects who received at least 1 dose of study drug.
- d Based on BLAST analysis the subject was determined to have genotype 1b HCV infection.
- e Of the 73 subjects enrolled in the study and received at least 1 dose of study drug, 71 subjects received the SOF/VEL FDC tablet formulation.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Clinical pharmacology

## 2.4.2.1. Population pharmacokinetics

The objectives of the Population Pharmacokinetic Analysis for Sofosbuvir, GS 331007, and Velpatasvir after Administration of Sofosbuvir + Ribavirin, Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin, or Sofosbuvir/Velpatasvir Fixed-Dose Combination in Pediatric Subjects with Hepatitis C Virus Infection were:

- To update a joint model evaluating the PK of SOF, GS-566500, and its primary metabolite, GS331007, in HCV-infected pediatric subjects administered SOF+ RBV, ledipasvir (LDV)/SOF FDC ±RBV, or SOF/VELFDC
- To develop a PopPK model for evaluating the PK of VEL in HCV-infected pediatric subjects administered SOF/VELFDC
- To evaluate the effects of demographic
- To support a simplified dosing recommendation for SOF/VEL FDC in pediatric subjects based on weight band.

## Dataset

Three Phase 2 studies (GS-US-334-1112, GS-US-337-1116 and GS-US-342-1143) in pediatric subjects with chronic HCV infection were used in the population PK modeling and are presented in the table below. Study GS-US-334-1112 evaluated SOF (administered once daily) + RBV for a treatment duration of 12 or 24 weeks in subjects aged 3 to &lt; 18 years old with chronic genotype 2 or 3 HCV infection. Study GS-US-337-1116 evaluated LDV/SOF FDC (administered once daily) ± RBV for a treatment duration of 12 or 24 weeks in subjects aged 3 to &lt;18 years old with chronic genotype 1, 3, 4, 5, or 6 HCV infection. Study GS-US-3421143 evaluated SOF/VEL FDC (administered once daily) for a treatment duration of 12 weeks in subjects aged 6 to &lt; 18 years with chronic HCV infection. PK sampling included a combination of intensive and sparse sampling. After all exclusions, a total of 69 subjects in Study GS-US-334-1112, 160 subjects in Study GS-US337-1116, and 148 subjects in Study GS-US-342-1143 had at least one measurable SOF concentration value included in the SOF joint model population PK analysis. A total of 70 subjects in Study GS-US-334-1112, 197 subjects in Study GS-US-334-1116, and 148 subjects in Study GS-US-334-1143 had at least one concentration value for GS-566500 included in the population PK analysis. A total of 85 Subjects in Study GSUS-334-1112, 198 subjects in Study GS-US-337-1116, and 153 subjects in Study GS-US-342-1143 had at least one concentration value for GS-331007 included in the population PK analysis.

The population PK data included 173 subjects from Study GS-US-342-1143 for VEL. After all exclusions, a total of 153 subjects in Study GS-US-342-1143 had at least one measurable concentration value for VEL.

<div style=\"page-break-after: always\"></div>

Table 2 Phase 2 studies (GS-US-334-1112, GS-US-337-1116 and GS-US-342-1143) in paediatric subjects with chronic HCV infection used in the population PK modelling

| Study                         | Age Group [yrs]   | Study Phase   | Subjects with PK Sampling (Intensive [Int] and/or Sparse)a   | Dosing Regimen (mg)6            |
|-------------------------------|-------------------|---------------|--------------------------------------------------------------|---------------------------------|
| GS-US-334-1112                | 12 to<18          | PK lead-in    | N= 10 (Int + Sparse in Treatment phase)                      | 400 SOF                         |
| GS-US-334-1112                | 12 to<18          | Treatment     | N= 42 (Sparse only)                                          | 400 SOF                         |
| SOF +RBVc                     | 6 to <12          | PK lead-in    | N = 12 (Int + Sparse im Treatment phase)                     | 200 SOF                         |
| SOF +RBVc                     | 6 to <12          | Treatment     | N= 29 (Sparse only)                                          | 200 SOF                         |
| SOF +RBVc                     | 3 to <6           | PK lead-in    | N = 11 (Int + Sparse in Treatment phase)                     | >17 kg: 200 S0F ≤17 kg: 150 S0F |
| SOF +RBVc                     | 3 to <6           | Treatment     | N= 1 (Sparse only)                                           | >17 kg: 200 S0F ≤17 kg: 150 S0F |
| GS-US-337-1116 LDV/SOF ± RBVd | 12 to<18          | PK lead-in    | N = 10 (Int + Sparse im Treatment phase)                     | 90/400 LDV/SOF                  |
| GS-US-337-1116 LDV/SOF ± RBVd | 12 to<18          | Treatment     | N= 90 (Sparse only)                                          | 90/400 LDV/SOF                  |
| GS-US-337-1116 LDV/SOF ± RBVd | 6 to ≤12          | PK lead-in    | N = 12 (Int + Sparse in Treatment phase)                     | 45/200 LDV/SOF                  |
| GS-US-337-1116 LDV/SOF ± RBVd | 6 to ≤12          | Treatment     | N= $0 (Sparse only)                                          | 45/200 LDV/SOF                  |
| GS-US-337-1116 LDV/SOF ± RBVd | 3 to <6           | PK lead-in    | N = 14 (Int + Sparse im Treatment phase)                     | > 17 kg: 45/200 LDV/SOF         |
| GS-US-337-1116 LDV/SOF ± RBVd | 3 to <6           | Treatment     | N= 8 (Sparse only) N = 12° (Int + Sparse in Treatment phase) | ≤ 17 kg: 33.75/150 LDV/SOF      |
| GS-US-342-1143 SOF VELF       | 12 to<18          | PK lead-in    | N = 17 (Int + Sparse in Treatment phase)                     | 400/100SOF/VEL                  |
| GS-US-342-1143 SOF VELF       | 12 to<18          | Treatment     | N= 85 (Sparse only)                                          | 400/100SOF/VEL                  |
| GS-US-342-1143 SOF VELF       | 6 to≤12           | PK lead-in    | N = 20 (Int + Sparse in Treatment phase)                     | 200/50SOF/VEL                   |
| GS-US-342-1143 SOF VELF       | 6 to≤12           | Treatment     | N= 51 (Sparse only)                                          | 200/50SOF/VEL                   |

Int = intensive; LDV = ledipasvir; N= number of subjects; PK = pharmacokinetic; RBV =ribavirin; SOF = gofosbuvir; VEL =velpatasvir.

Protocol-defined dosing regimen based on defined age and weight cutoff.

For sparse PK sampling, single blood gamples were collected at all on-treatment study visits.

old.

Intensive PK sampling included 9 time points for pediatric subjects 6 to &lt; 18years old and 6 time points for pediatrie subjects 3 to &lt; 6 years old. Pediatrie subjects 3 to &lt; 6 years old could have participated im an optional intensive PK substudy that included 9 time points at Week 4 or 8 of treatment.

Intensive PK sampling included 9 time points for pediatric subjects 6 to &lt; 18 years old.

- One subject participated in both the PK lead-in phase and the intensive PK substudy during the treatment phase.

## SOF popPK model development

A previously developed PopPK models using 2 of the 3 studies (GS-US-334- 1112 and GS-US-337- 1116) was updated with data from GS-US-342-1143 also included in the dataset. The structural model is a joint model for parent and metabolites, depicting the metabolism of SOF to the intermediate metabolite, GS-566500, which is subsequently metabolized to and cleared from the body as GS-331007, is illustrated in figure below (Figure 1). The model included, a priori, the effect of baseline WT (allometric exponents fixed to 0.75 and 1 for clearances and volumes, respectively) on CLSOF, VSOF, CL500, V500, CL007, and Vc007. Based on previous population PK analysis and the expected effect of LDV, VEL, and RBV on the PK of SOF and its metabolites, the model also included (a priori) coadministration of LDV and VEL separately on SOF F1 and coadministration of RBV on CL500and CL007. Following the covariate search, statistically significant covariates of age on CL500and CL007and also sex on CL007were included in the model. Bootstrap resampling techniques were used to evaluate the model stability and confidence interval (CI) of the final parameter estimates (Table 5). This model evaluation consisted of repeatedly fitting the model to a large number (n= 1000) of bootstrap replicates of the dataset.

<div style=\"page-break-after: always\"></div>

Figure 1 Population PK Model Diagram for SOF and SOF Metabolites

## PopPKMfodelforSOFJointModel

<!-- image -->

ALAG=aboption lagtimeCLoo= clearance ofGS-331007;CLo = clearance ofGS-566500,CLror= clearance ofSOF；D1= duration of zero crderinput F1=relative factonabscrbed;Ka007=fnst-rder abspticnrate constant ofGS-331007;Ka500=finst-orderabspticnrate cotant ofGS-566500;KaSOF= first-order absorption rate constant of SOF; PopPK = population phanmacokcinetic;SOF = sofosbuis.

Table 3 Comparison of final model estimates and bootstrap results for SOF

## Comparison of Final Mfodel Estimates andBootstrapResults

| Paramrter   | Paramsrter Deseription                             | Estimate [RSE]   | Bootstrap EstimateMlediam[2.5 97.5aPercentiles]   | SIR Median [2.54, 97.54 Percentiles]   |
|-------------|----------------------------------------------------|------------------|---------------------------------------------------|----------------------------------------|
| ep(0)       | Absrpin rae fe SOF (1h)                            |                  | 127[1.14:14]                                      | 1.25 [1.19;13]                         |
| ep(0)       | Ab for GS-566500 (1/)                              |                  | 0.291[0.274;0.313]                                | 0.292 [0.281;0.304]                    |
|             | Absorption rate for GS-331007 (1/br)               |                  | 0.023 [0.0201;0.0264]                             | [8900                                  |
| (olda       | Agpwt oral dence cf SOF (L)                        | 304[6]           | 302 [268;341]                                     | 305 [276;339]                          |
| ep(0)       | Appet cl volme ofSOF (L)                           | 148[15]          | 154 [110;203]                                     | 156 [120,196]                          |
| epa)        | Apparent eral clearance of GS-566500 (Lhr)         | 811[]            | 811[766,855]                                      | 822[772;871]                           |
| exp(0)      | Apparent ceal ole ofGS-566500 (L)                  | 1190[]           | 1180[1010;1370]                                   | 110 [1110;1270]                        |
| ep(o)       | Apparent eal cleace of GS-331007 (L/hr)            | 169 [2]          | 167[160;174]                                      | 166[160;173]                           |
| (okda       | Appareet cental volumme of GS-331007 (L)           | 212[5]           | 212 [190;245]                                     | [06]2                                  |
| cxp(0a)     | Apparent inercompartmtal clearance cf GS-331007（L） | 47.6[9]          | 52.2 [39.6;74.8]                                  | 49.A[42.4;57]                          |
| exp(0h:)    | Apparent pnphl volme of GS-331007(L)               | 1030[21]         | 1100 [172;1840]                                   | 1090 [707;1540]                        |
| exp(0:)     | Absorption duration for SOF (ht)                   | 0.609[7]         | 0.61 [0.482;0.8]                                  | 0.597 [0.507;0.688]                    |
|             | F1 for SOF                                         | 1[Fived]         | ==                                                | -                                      |
| 0hs         | F1 for GS-331007                                   | 7.18 [Fixed]     | 7.18 [7.18;7.18]                                  | ==                                     |
|             | Ledipnir  FI fr SOF                                | 0.769[Fixed]     | 0.769 [0.769,0.769]                               |                                        |
|             | F1 for GS-566500                                   | 5.32 [Fixed]     | 5.32 [5.32;5.32]                                  |                                        |
|             | Proportionaleor SDfor GS-566500                    | 0.603 [2]        | 0.602 [0.577;0.628]                               | 0.602 [0.585;0.625]                    |
| 0           | Proportioeal eror SD for GS-331007                 | 0.306[1]         | 0.305 [0.292;0.317]                               | 0.305 [0.296;0.313]                    |
| exp(0a)     | Aboerption lag time foe GS-331007                  | 2                | [0.5;11.5]                                        | 3.01 [2.91;3.12]                       |
| 019         | Preportional eor SD fr SOF                         | 0.93[3]          | 0.927 [0.888;0.968]                               | 0.934 [0.873;0.979]                    |
| exp(0s)     | Oral clearance ofGS-566500+RBV(Lh)                 | 1240 [4]         | 1260 [1170;1350]                                  | 1240 [1160;1360]                       |
| exp(oe)     | Oral clearance cfGS-331007+RBV(L/hr)               | 188[3]           | 186[174;197]                                      | 186[175;197]                           |
| exp(0)      | Absception lag time fee SOF (hr)                   | 0.0821[Fixd]     | 0.0821 [0.0821;0.0821]                            |                                        |
| Oes         | Velptvir eF for SOF                                | 1.4[9]           | 1.41 [1.05;1.79]                                  | 1.42 [1.17;1.61]                       |
| 0a          | Age effect on clearanoe of Gs-331007               | 0.17[19]         | -0.184[0.24;0.123]                                | [s1r060]1810                           |
| 0:          | Sex effect on clearamce of GS-331007               | 0.101 [31]       | 0.105 [0.0521;0.16]                               | 0.0998 [0.0417;0.163]                  |
| 0           | Age effeet on clme o GS-566500                     | -0.239[20]       | -0.241 [-0.332;-0.163]                            | [61o-1rEo-]ssto                        |
| ou          | Betweebject i n cl f SOF                           | 80%[11]          | 76.7 [64.9,87.4]                                  | 80 [69.5,91.1]                         |
|             | Betweenjectre n me fSOF                            | 224%[13]         | 204 [151;337]                                     | 212 [190;237]                          |
| 01212       | GS-566500                                          | 32%[22]          | 32.3 [27.9,40.3]                                  | 33.7 [29.5;37.7]                       |
|             | Between sbject arince n clearace of GS-331007      | 27%[9]           | 27.2 [25.2;29.3]                                  | 27.7 [25;29.3]                         |

SOF

Fct ard, R En rr, SD e d S  ar , Sing  ng

RSE is defied a te SE dide by th al valoe of te etiat Ce × 100 or maod pren an a SE × 100% for log-oe paramten.

Sec:053-go6fnl-20190706.R

<div style=\"page-break-after: always\"></div>

## VEL popPK model development

A previous popPK model developed for VEL based on adult data was used as a starting point. The model was a 2-compartment model with first-order absorption, first-order elimination from the central compartment, and an absorption lag time (ALAG) (Figure 2). The model was updated using the updated dataset with data from Study GS-US-342-1143 added. The effect of WT on CL/F and Vc/F were included using fixed allometric exponents of 0.75 and 1, respectively. No additional covariates were included in the updated model. Bootstrap resampling techniques were used to evaluate the model stability and confidence interval (CI) of the final parameter estimate (N=1000) (Table 6).

Figure 2 Population PK Model Diagram for VEL

<!-- image -->

GI = gastrointestinal; k, = first-order absorption rate constant; k  elimination rate constant; k:y  rate constant from central to peripheral; kg:  rate constant from peripheral to central; CL/F = apparent central oral clearanee: PepPK = population pharmacokinetie; QF = apparent inter-compartmental clearance; Ve/F = apparent central volumc; VEL = velpatawvir, VpF = apparent peripheral volume.

Table 4 Table x Comparison of final model estimates and bootstrap results for VEL

## Comparison of Final Model Estimates and Bootstrap Results for VEL

| Parameter   | Parameter Dereription                                  | Final PopPK Mlodel Estimates [RSE%]   | Bootstrap Final Mfodel Median [2.5h, 97.5* Percentiles]   | SIR MIedian [2.5°, 97.5* Percentiles]   |
|-------------|--------------------------------------------------------|---------------------------------------|-----------------------------------------------------------|-----------------------------------------|
| (o)dxe      | Apparent oral elearance for VEL, CL/F (L/)             | 23.5 [5]                              | 22.6 [9.71;25.8]                                          | 23.5 [21.7;25.7]                        |
| exp(02)     | Apparent cental volume for VEL, Ve/F (L)               | 25.3 [13]                             | 25.4 [19.5;33.3]                                          | 25.3 [20.2;30.7]                        |
| (o)dx)      | Apparent imter-compartment clearance for VEL,QF (L/hr) | 1.09 [48]                             | 1.51 [0.405;11.9]                                         | 1.11 [0.598;1.92]                       |
| exp(0)      | Apparent peripharal volume for VEL, Vp/F (L)           | 577 [91]                              | 713 [43.2;562000]                                         | 621 [163;3280]                          |
| exp(0s)     | Abtorption rate constant fer VEL, k, (hr*)             | 0.116 [6]                             | 0.116 [0.103;0.133]                                       | 0.116 [0.107;0.126]                     |
| exp(0)      | Abiorption lg time for VEL, ALAG (hr)                  | 0.457 [2]                             | 0.458 [0.44;0.479]                                        | 0.457 [0.443;0.473]                     |
|             | Residual enor for VEL (9)                              | 79 [3]                                | 79.5 [76.1;82.8]                                          | 79.5 [77.6;81.7]                        |
| DCLF        | IIV ofCL/F (%)                                         | 52 [27]                               | 54.7 [38;113]                                             | 52.4 [45.4;61.3]                        |
|             | IV ofVeF ()                                            | 83 [25]                               | $0.9 [59.6;101]                                           | 84.1 [64;101]                           |
|             | IV ofk,(%)                                             | 21 [37]                               | 20.3 [11.1;27.7]                                          | 21.1 [14.3;27.8]                        |

tntercomparumestal cleannee; RSE = residusl squared eror, SIR = sampling imporunce resmpling; VeF  apparent cental vohume; VEL = velpauvir, VpF = opparent peripheral vohme. Sowrce: vel-gof-fmal-20190606.R.

<div style=\"page-break-after: always\"></div>

## Model evaluation

The pcVPC evaluated the ability of the model to reproduce the distribution of the data despite variable dosing/sampling regimens. Prediction-corrected visual predictive check simulations were performed as a validation of the final PopPK model. A total of 1000 replicates of the studies were simulated using the final PopPK model parameter estimates, the estimated subject-specific ETA, and the residual variability.

The pcVPC of SOF plasma concentration-time profiles and its metabolites stratified by age group are shown in Figure 3. The pcVPC plots show that the final SOF joint PopPK model adequately predicted the central tendency and variability of plasma SOF, GS-566500, and GS-331007 concentrations in the paediatric patient population.

The pcVPC of VEL plasma concentration-time profiles are shown Figure 4. The pcVPC plots show that the final VEL PopPK model adequately predicted the central tendency and variability of the plasma VEL concentrations in the pediatric patient population. The 5 th  percentile associated with the second bin in both age categories is found to be outside the 95% CI of the model-predicted 5 th  percentile; this is explained by few individual observations that deviate significantly from the overall population at that specific time interval.

Figure 3 Prediction-corrected VPC of Plasma Concentration-Time Profiles for SOF and SOF Metabolites Stratified by Age Groups

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4 Prediction-corrected VPC of Plasma Concentration-Time Profiles for VEL Stratified by Age

pcVPCof Plasma Concentration-TimeProfilesforVEL Stratified by Age (12 to&lt;1Sand 6to&lt;12 Years)

<!-- image -->

Te pePC plots show te medin(sod blacklines） an spread (5 to 95perentle, dased black lin) of the observed ooentations in all objects. The red area is 9fidnef  m  baa th 95cf in fthe i an 95peThe peVPCfor adolesce (12 to ≤ 18y)in pented in the left panel,and epeVPC for ects 6 to12 yean cld is preted in he igt pl So7oe:1el-mof-fnal-20190606.R

pePCpeediesee-coreoedvisualpeedetcbackVEL=selpatan

Simulated exposures for SOF/VEL in paediatric subjects following the proposed WT-band based dosing regimen were largely contained within the range of exposure observed in the adult Phase 2/3 population. Sofosbuvir and GS-331007 exposures were inversely correlated with WT, with a percent change in SOF/GS331007 exposures ranging from -42.2% to +119% (relative to the median exposures) for subjects with extreme covariate values (ie, 5 th  and 95 th  WT percentile, respectively).

Figure 5 Simulated SOF Exposures by Proposed Weight Band-Based Dosing

Simulated Steady-StateSOFand GS-331007AUCuuand CmaxFollowingtheProposed WeightBand-Based DosingRecommendation inPediatrie Subjects (6 to&lt;18yearsold)WhoReceived SOF/VEL

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 6 Sensitivity Plot for SOF and GS-331007 AUCtau and Cmax

<!-- image -->

Velpatasvir exposures were inversely correlated with WT, with a percent change in VEL exposures ranging from -41.7% to +81.1% (relative to the median exposures) for subjects with extreme covariate values (ie, 5 th  and 95thWT percentile, respectively).

Figure 7 Simulated SOF Exposures by Proposed Weight Band-Based Dosing

Simulated Steady-State VELAUCu=,Cmn,and CuuFollowingtheProposed Weight-Band-Based Dosing Recommendation in Pediatrie Subjects (6 to&lt; 18Years Old)Who Received SOF/VEL

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 8 Sensitivity Plot for VEL AUCtau and Cmax

<!-- image -->

<!-- image -->

## Weight based dosing

Exposures within the adult range have been shown to be associated with high SVR rates, a favorable safety profile, and a lack of association between exposures and AEs.

During the ongoing procedure, Gilead proposes an update to the dosing regimen to allow administration of the SOF/VEL400/100mg tablet to children weighing ≥ 30kg in lieu of limiting treatment to those weighing ≥ 35 kg. Gilead believes the data presented herein supports the lower weight band and does not impact the safety profile of SOF/VEL in pediatric patients within the 30 to 35kg weight range. The CHMP agreed to assess this new data within the current extension. The simulations presented below and the accompanying changes to the SmPC to incorporate the 30 kg cut-point and ensure a greater proportion of children in the 30 to &lt;35kg weight range have VEL Ctau values within the range of those observed in the adult population. Simulated exposures of SOF, GS-331007, and VEL in children weighing ≥ 30  kg administered SOF/VEL 400/100mg and children weighing 17 to &lt;30 kg administered SOF/VEL 200/50mg are shown graphically in Figure 9, Figure 10, and Figure 11, respectively along with their corresponding comparison to the observed exposures in adults in Table 7, Table 8, and Table 9, respectively. These comparisons show that administration of the 400/100mg dose to children weighing &gt;30 kg will decrease the percentage of children (in the applicable weight band of 30 to 40 kg) with Ctau values below the 5 th  percentile of adults from 12% to 4% for VEL. A modest increase is projected in the percentage of children with AUCtau and Cmax above the 95 th  percentile of adults for all analytes (SOF, GS-331007, and VEL).

<div style=\"page-break-after: always\"></div>

Figure 9 Original and Proposed Epclusa Weight-Band Simulations for SOF

Table 5 Proposed Epclusa Weight Band Simulations for SOF AUCtau and Cmax

<!-- image -->

Table 1. Proposed Epclusa Weight Band Simulations for SOF AUCtau and Cmax

|              | SOF PK    | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   |
|--------------|-----------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Weight Group | Parameter | ConfidenceInterval Outside90%                                    | ConfidenceInterval Outside90%                                    | AboveMax                                                         | AboveMax                                                         | Above95thPercentile                                              | Above95thPercentile                                              | Below5thPercentile                                               | Below5thPercentile                                               | Below Min                                                        | Below Min                                                        |
|              |           | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17to <30 kg and ≥30 kg                                           | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17to <35 kg and ≥35 kg                                           | 17 to <30kg and ≥30 kg                                           |
| 17-20 kg     |           | 67.8                                                             | 67.8                                                             | 22.4                                                             | 22.4                                                             | 64.3                                                             | 64.3                                                             | 3.5                                                              | 3.5                                                              | 0.3                                                              | 0.3                                                              |
| 20-30 kg     |           | 60.1                                                             | 60.1                                                             | 15.2                                                             | 15.2                                                             | 54.2                                                             | 54.2                                                             | 6                                                                | 6                                                                | 0.8                                                              | 0.8                                                              |
| 30-40 kg     |           | 63.5                                                             | 75.9                                                             | 19.3                                                             | 31.4                                                             | 57.6                                                             | 74.2                                                             | 5.9                                                              | 1.7                                                              | 0.9                                                              | 0.1                                                              |
| 40-50 kg     |           | 69                                                               | 69                                                               | 22.9                                                             | 22.9                                                             | 65.9                                                             | 65.9                                                             | 3.1                                                              | 3.1                                                              | 0.3                                                              | 0.3                                                              |
| 50-60 kg     |           | 63.5                                                             | 63.5                                                             | 18.4                                                             | 18.4                                                             | 58.8                                                             | 58.8                                                             | 4.7                                                              | 4.7                                                              | 0.5                                                              | 0.5                                                              |
| 60-70 kg     | AUC       | 59.1                                                             | 59.1                                                             | 14.6                                                             | 14.6                                                             | 52.9                                                             | 52.9                                                             | 6.2                                                              | 6.2                                                              | 0.9                                                              | 0.9                                                              |
| 70-80 kg     |           | 55.9                                                             | 55.9                                                             | 11.1                                                             | 11.1                                                             | 47.2                                                             | 47.2                                                             | 8.7                                                              | 8.7                                                              | 1.3                                                              | 1.3                                                              |
| 80-90 kg     |           | 52.2                                                             | 52.2                                                             | 9                                                                | 9                                                                | 42                                                               | 42                                                               | 10.2                                                             | 10.2                                                             | 1.6                                                              | 1.6                                                              |
| 90-100kg     |           | 51.4                                                             | 51.4                                                             | 6.8                                                              | 6.8                                                              | 37.7                                                             | 37.7                                                             | 13.7                                                             | 13.7                                                             | 3                                                                | 3                                                                |
| 100 kg+      |           | 47.8                                                             | 47.8                                                             | 5.6                                                              | 5.6                                                              | 31.8                                                             | 31.8                                                             | 16                                                               | 16                                                               | 3.4                                                              | 3.4                                                              |
| 17-20 kg     |           | 73.3                                                             | 73.3                                                             | 40.6                                                             | 40.6                                                             | 64.2                                                             | 64.2                                                             | 1'6                                                              | 9.1                                                              | 2.3                                                              | 2.3                                                              |
| 20-30 kg     |           | 68.7                                                             | 68.7                                                             | 31.8                                                             | 31.8                                                             | 55.5                                                             | 55.5                                                             | 13.2                                                             | 13.2                                                             | 3.8                                                              | 3.8                                                              |
| 30-40 kg     |           | 70.4                                                             | 77.8                                                             | 34.6                                                             | 48.9                                                             | 56.9                                                             | 70.4                                                             | 13.5                                                             | 7.4                                                              | 4                                                                | 1.8                                                              |
| 40-50 kg     |           | 73.5                                                             | 73.5                                                             | 40.1                                                             | 40.1                                                             | 63.2                                                             | 63.2                                                             | 10.3                                                             | 10.3                                                             | 2.7                                                              | 2.7                                                              |
| 50-60 kg     |           | 70.1                                                             | 70.1                                                             | 33.6                                                             | 33.6                                                             | 57                                                               | 57                                                               | 13.1                                                             | 13.1                                                             | 3.8                                                              | 3.8                                                              |
| 60-70 kg     | C         | 67.2                                                             | 67.2                                                             | 28.4                                                             | 28.4                                                             | 51.1                                                             | 51.1                                                             | 16.2                                                             | 16.2                                                             | 5.2                                                              | 5.2                                                              |
| 70-80kg      |           | 65.6                                                             | 65.6                                                             | 24                                                               | 24                                                               | 47                                                               | 47                                                               | 18.6                                                             | 18.6                                                             | 6.5                                                              | 6.5                                                              |
| 80-90 kg     |           | 63                                                               | 63                                                               | 20.1                                                             | 20.1                                                             | 42                                                               | 42                                                               | 21                                                               | 21                                                               | 7.4                                                              | 7.4                                                              |
| 90-100 kg    |           | 60.9                                                             | 60.9                                                             | 16.2                                                             | 16.2                                                             | 36.7                                                             | 36.7                                                             | 24.2                                                             | 24.2                                                             | 8.5                                                              | 8.5                                                              |
| 100 kg+      |           | 61                                                               | 61                                                               | 12.8                                                             | 12.8                                                             | 32.2                                                             | 32.2                                                             | 28.8                                                             | 28.8                                                             | 10.9                                                             | 10.9                                                             |

<div style=\"page-break-after: always\"></div>

Figure 10 Original and Proposed Epclusa Weight-Band Simulations for GS-331007

Figure 2. Original and Proposed Epclusa Weight-Band Simulations for GS-331007

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 6 Proposed Epclusa Weight Band Simulations for GS-331007 AUCtau and Cmax

| Weight    | GS-331007 PK   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   |
|-----------|----------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Group     | Parameter      | Outside 90% Confidence Interval                                  | Outside 90% Confidence Interval                                  | Above Max                                                        | Above Max                                                        | Above 95tPercentile                                              | Above 95tPercentile                                              | Below5*\"Percentile                                               | Below5*\"Percentile                                               | Below Min                                                        | Below Min                                                        |
|           |                | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30kg and ≥30 kg                                           | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35kg and ≥35 kg                                           | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          |
| 17-20 kg  | AUCau          | 11.5                                                             | 11.5                                                             | 0                                                                | 0                                                                | 5.2                                                              | 5.2                                                              | 6.3                                                              | 6.3                                                              | 0                                                                | 0                                                                |
| 20-30 kg  | AUCau          | 18.2                                                             | 18.2                                                             | 0                                                                | 0                                                                | 1.6                                                              | 1.6                                                              | 16.6                                                             | 16.6                                                             | 0.4                                                              | 0.4                                                              |
| 30-40 kg  | AUCau          | 34.3                                                             | 33.5                                                             | 0                                                                | 0.1                                                              | 14.8                                                             | 33.1                                                             | 19.5                                                             | 0.4                                                              | 1                                                                | 0                                                                |
| 40-50 kg  | AUCau          | 17.8                                                             | 17.8                                                             | 0                                                                | 0                                                                | 16.4                                                             | 16.4                                                             | 1.5                                                              | 1.5                                                              | 0                                                                | 0                                                                |
| 50-60 kg  | AUCau          | 11.8                                                             | 11.8                                                             | 0                                                                | 0                                                                | 7.5                                                              | 7.5                                                              | 4.2                                                              | 4.2                                                              | 0                                                                | 0                                                                |
| 60-70 kg  | AUCau          | 12.3                                                             | 12.3                                                             | 0                                                                | 0                                                                | 3.2                                                              | 3.2                                                              | 9.2                                                              | 9.2                                                              | 0.1                                                              | 0.1                                                              |
| 70-80 kg  | AUCau          | 17.8                                                             | 17.8                                                             | 0                                                                | 0                                                                | 1.4                                                              | 1.4                                                              | 16.4                                                             | 16.4                                                             | 0.3                                                              | 0.3                                                              |
| 80-90 kg  | AUCau          | 26.4                                                             | 26.4                                                             | 0                                                                | 0                                                                | 0.6                                                              | 0.6                                                              | 25.8                                                             | 25.8                                                             | 0.7                                                              | 0.7                                                              |
| 90-100 kg | AUCau          | 45.1                                                             | 45.1                                                             | 0                                                                | 0                                                                | 0.2                                                              | 0.2                                                              | 44.9                                                             | 44.9                                                             | 3.2                                                              | 3.2                                                              |
| 100 kg+   | AUCau          | 57.7                                                             | 57.7                                                             | 0                                                                | 0                                                                | 0.1                                                              | 0.1                                                              | 57.7                                                             | 57.7                                                             | 7                                                                | 7                                                                |
| 17-20 kg  | Cmax           | 40.8                                                             | 40.8                                                             | 0.7                                                              | 0.7                                                              | 40.7                                                             | 40.7                                                             | 0.1                                                              | 0.1                                                              | 0                                                                | 0                                                                |
| 20-30 kg  | Cmax           | 17.5                                                             | 17.5                                                             | 0.1                                                              | 0.1                                                              | 16.7                                                             | 16.7                                                             | 0.8                                                              | 0.8                                                              | 0                                                                | 0                                                                |
| 30-40 kg  | Cmax           | 41.4                                                             | 80.4                                                             | 5.1                                                              | 13.7                                                             | 39.2                                                             | 80.4                                                             | 2.2                                                              | 0                                                                | 0                                                                | 0                                                                |
| 40-50 kg  | Cmax           | 58.1                                                             | 58.1                                                             | 2.7                                                              | 2.7                                                              | 58.1                                                             | 58.1                                                             | 0                                                                | 0                                                                | 0                                                                | 0                                                                |
| 50-60 kg  | Cmax           | 35.2                                                             | 35.2                                                             | 0.5                                                              | 0.5                                                              | 35.1                                                             | 35.1                                                             | 0.1                                                              | 0.1                                                              | 0                                                                | 0                                                                |
| 60-70 kg  | Cmax           | 18.7                                                             | 18.7                                                             | 0.1                                                              | 0.1                                                              | 18.2                                                             | 18.2                                                             | 0.5                                                              | 0.5                                                              | 0                                                                | 0                                                                |
| 70-80 kg  | Cmax           | 9.3                                                              | 9.3                                                              | 0                                                                | 0                                                                | 8                                                                | 8                                                                | 1.4                                                              | 1.4                                                              | 0                                                                | 0                                                                |
| 80-90 kg  | Cmax           | 6.2                                                              | 6.2                                                              | 0                                                                | 0                                                                | 3.2                                                              | 3.2                                                              | 3                                                                | 3                                                                | 0                                                                | 0                                                                |
| 90-100 kg | Cmax           | 9.6                                                              | 9.6                                                              | 0                                                                | 0                                                                | 0.5                                                              | 0.5                                                              | 9.1                                                              | 9.1                                                              | 0                                                                | 0                                                                |
| 100kg+    | Cmax           | 20.6                                                             | 20.6                                                             | 0                                                                | 0                                                                | 0.3                                                              | 0.3                                                              | 20.3                                                             | 20.3                                                             | 0.3                                                              | 0.3                                                              |

<div style=\"page-break-after: always\"></div>

Figure 11 Original and Proposed Epclusa Weight-Band Simulations for VEL

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 7 Proposed Epclusa Weight Band Simulations for VEL AUCtau, Cmax and Ctau

| Weight                                                                                                               | VEL PK    | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   | Percentage of PediatricSubjects Outside of Adult Exposure(%)   |
|----------------------------------------------------------------------------------------------------------------------|-----------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Group                                                                                                                | Parameter | Confidence Interval Outside 90%                                | Confidence Interval Outside 90%                                | Above Max                                                      | Above Max                                                      | Above 95t\" Percentile                                          | Above 95t\" Percentile                                          | Below5 Percentile                                              | Below5 Percentile                                              | Below Min                                                      | Below Min                                                      |
|                                                                                                                      |           | 17 to <35 kg and ≥35 kg                                        | 17 to <30 kg and ≥30 kg                                        | 17to <35 kg and ≥35 kg                                         | 17 to <30 kg and ≥30 kg                                        | 17 to <35 kg and ≥35 kg                                        | 17to <30 kg and ≥30 kg                                         | 17 to <35 kg and ≥35 kg                                        | 17 to <30 kg and ≥30 kg                                        | 17 to <35 kg and ≥35 kg                                        | 17 to <30 kg and ≥30 kg                                        |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 23.1                                                           | 23.1                                                           | 1.1                                                            | 1.1                                                            | 22.4                                                           | 22.4                                                           | 0.7                                                            | 0.7                                                            | 0                                                              | 0                                                              |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 14.7                                                           | 14.7                                                           | 0.4                                                            | 0.4                                                            | 12.7                                                           | 12.7                                                           | 2                                                              | 2                                                              | 0.1                                                            | 0.1                                                            |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 23.8                                                           | 41                                                             | 2                                                              | 5                                                              | 21.3                                                           | 40.8                                                           | 2.5                                                            | 0.2                                                            | 0.1                                                            | 0                                                              |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 27.5                                                           | 27.5                                                           | 2.1                                                            | 2.1                                                            | 26.9                                                           | 26.9                                                           | 0.6                                                            | 0.6                                                            | 0                                                              | 0                                                              |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 20.2                                                           | 20.2                                                           | 1.1                                                            | 1.1                                                            | 19                                                             | 19                                                             | 1.2                                                            | 1.2                                                            | 0                                                              | 0                                                              |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 15.3                                                           | 15.3                                                           | 0.6                                                            | 0.6                                                            | 13.1                                                           | 13.1                                                           | 2.2                                                            | 2.2                                                            | 0.1                                                            | 0.1                                                            |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 12.8                                                           | 12.8                                                           | 0.2                                                            | 0.2                                                            | 9.2                                                            | 9.2                                                            | 3.6                                                            | 3.6                                                            | 0.2                                                            | 0.2                                                            |
| 17-20 kg 20-30 kg 30-40 kg 40-50 kg 50-60 kg 60-70 kg 70-80 kg 80-90 kg 90-100 kg 100 kg+ 17-20 kg 20-30 kg 30-40 kg | AUCtau    | 11.8                                                           | 11.8                                                           | 0.2                                                            | 0.2                                                            | 6.6                                                            | 6.6                                                            | 5.2                                                            | 5.2                                                            | 0.2                                                            | 0.2                                                            |
|                                                                                                                      | AUCtau    | 11.9                                                           | 11.9                                                           | 0.2                                                            | 0.2                                                            | 4.6                                                            | 4.6                                                            | 7.3                                                            | 7.3                                                            | 0.4                                                            | 0.4                                                            |
|                                                                                                                      | AUCtau    | 14.6                                                           | 14.6                                                           | 0                                                              | 0                                                              | 2.8                                                            | 2.8                                                            | 11.8                                                           | 11.8                                                           | 1.1                                                            | 1.1                                                            |
|                                                                                                                      | Cmax      | 22                                                             | 22                                                             | 1.2                                                            | 1.2                                                            | 21.9                                                           | 21.9                                                           | 0.1                                                            | 0.1                                                            | 0                                                              | 0                                                              |
|                                                                                                                      | Cmax      | 11.5                                                           | 11.5                                                           | 0.4                                                            | 0.4                                                            | 11                                                             | 11                                                             | 0.4                                                            | 0.4                                                            | 0                                                              | 0                                                              |
|                                                                                                                      | Cmax      | 20.2                                                           | 39.5                                                           | 1.8                                                            | 4.7                                                            | 19.5                                                           | 39.5                                                           | 0.7                                                            | 0                                                              | 0                                                              | 0                                                              |
| 40-50 kg                                                                                                             | Cmax      | 23.6                                                           | 23.6                                                           | 1.6                                                            | 1.6                                                            | 23.6                                                           | 23.6                                                           | 0.1                                                            | 0.1                                                            | 0                                                              | 0                                                              |
| 50-60 kg                                                                                                             | Cmax      | 15.2                                                           | 15.2                                                           | 0.7                                                            | 0.7                                                            | 15                                                             | 15                                                             | 0.2                                                            | 0.2                                                            | 0                                                              | 0                                                              |
| 60-70 kg                                                                                                             | Cmax      | 10.1                                                           | 10.1                                                           | 0.3                                                            | 0.3                                                            | 9.5                                                            | 9.5                                                            | 0.6                                                            | 0.6                                                            | 0                                                              | 0                                                              |
| 70-80 kg                                                                                                             | Cmax      | 6.9                                                            | 6.9                                                            | 0.1                                                            | 0.1                                                            | 5.9                                                            | 5.9                                                            | 1                                                              | 1                                                              | 0                                                              | 0                                                              |
| 80-90 kg                                                                                                             | Cmax      | 5.2                                                            | 5.2                                                            | 0.1                                                            | 0.1                                                            | 3.7                                                            | 3.7                                                            | 1.6                                                            | 1.6                                                            | 0                                                              | 0                                                              |
| 90-100 kg                                                                                                            | Cmax      | 5                                                              | 5                                                              | 0                                                              | 0                                                              | 2.4                                                            | 2.4                                                            | 2.6                                                            | 2.6                                                            | 0                                                              | 0                                                              |
| 100 kg+                                                                                                              | Cmax      | 7.1                                                            | 7.1                                                            | 0                                                              | 0                                                              | 1.2                                                            | 1.2                                                            | 5.9                                                            | 5.9                                                            | 0.1                                                            | 0.1                                                            |

|              | VELPK     | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   | Percentage of Pediatric Subjects Outside of Adult Exposure (%)   |
|--------------|-----------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Weight Group | Parameter | ConfidenceInterval Outside 90%                                   | ConfidenceInterval Outside 90%                                   | Above Max                                                        | Above Max                                                        | Above95\"Percentile                                               | Above95\"Percentile                                               | Below5 Percentile                                                | Below5 Percentile                                                | Below Min                                                        | Below Min                                                        |
|              |           | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          | 17 to <35 kg and ≥35 kg                                          | 17 to <30 kg and ≥30 kg                                          |
| 17-20 kg     | Ctau      | 19.3                                                             | 19.3                                                             | 0.6                                                              | 0.6                                                              | 12.2                                                             | 12.2                                                             | 7                                                                | 7                                                                | 0.2                                                              | 0.2                                                              |
| 20-30 kg     | Ctau      | 20.2                                                             | 20.2                                                             | 0.3                                                              | 0.3                                                              | 7.8                                                              | 7.8                                                              | 12.4                                                             | 12.4                                                             | 0.6                                                              | 0.6                                                              |
| 30-40 kg     | Ctau      | 24.3                                                             | 25.6                                                             | 1                                                                | 2.1                                                              | 12.2                                                             | 21.5                                                             | 12.1                                                             | 4.1                                                              | 0.7                                                              | 0.1                                                              |
| 40-50 kg     | Ctau      | 22                                                               | 22                                                               | 1.2                                                              | 1.2                                                              | 15.1                                                             | 15.1                                                             | 7                                                                | 7                                                                | 0.3                                                              | 0.3                                                              |
| 50-60 kg     | Ctau      | 21.5                                                             | 21.5                                                             | 0.9                                                              | 0.9                                                              | 11.7                                                             | 11.7                                                             | 9.8                                                              | 9.8                                                              | 0.4                                                              | 0.4                                                              |
| 60-70 kg     | Ctau      | 21.8                                                             | 21.8                                                             | 0.5                                                              | 0.5                                                              | 9.1                                                              | 9.1                                                              | 12.7                                                             | 12.7                                                             | 0.7                                                              | 0.7                                                              |
| 70-80 kg     | Ctau      | 23.9                                                             | 23.9                                                             | 0.4                                                              | 0.4                                                              | 7.5                                                              | 7.5                                                              | 16.5                                                             | 16.5                                                             | 1.1                                                              | 1.1                                                              |
| 80-90 kg     | Ctau      | 25.9                                                             | 25.9                                                             | 0.2                                                              | 0.2                                                              | 6.3                                                              | 6.3                                                              | 19.6                                                             | 19.6                                                             | 1.4                                                              | 1.4                                                              |
| 90-100 kg    | Ctau      | 28.3                                                             | 28.3                                                             | 0.2                                                              | 0.2                                                              | 6                                                                | 6                                                                | 22.3                                                             | 22.3                                                             | 2.1                                                              | 2.1                                                              |
| 100 kg+      | Ctau      | 31.3                                                             | 31.3                                                             | 0.2                                                              | 0.2                                                              | 4.2                                                              | 4.2                                                              | 27.1                                                             | 27.1                                                             | 3.1                                                              | 3.1                                                              |

## 2.4.3. Discussion on clinical pharmacology

A population PK analysis was performed where all sofosbuvir data has been pooled, and a joint model of SOF and metabolites and a separate popPK model for VEL were developed. Adequate non-linear mixed effects modelling methods have been used.

There is a slight overprediction of SOF trough concentration in the paediatric subjects, which would result in more conservative estimates of exposures with respect to safety. There is also a slight underprediction of the

<div style=\"page-break-after: always\"></div>

absorption phase for GS-566500 in the 12 &lt; 18-year-old age group. However, overall the model diagnostics indicate that the sofosbuvir model adequately represents the observed data in the paediatric population and the model is considered adequate to use in simulations to support the dose selection.

The population PK simulated exposures metrics have been compared with the corresponding observed exposure ranges in the adult population.

The CHMP considered that the AUC and Cmax for SOF are higher than the adult exposures. However, much higher exposures in adults with renal impairment have been observed with no dose adjustment required. Overall, given the safety profile of SOF and associated metabolites, the exposure levels in the paediatric population are acceptable.

Simulated velpatasvir exposures were similar to the ones in adults. Patients with extreme covariate values had 81 % higher Cmax and 75 % higher AUC. Based on a favourable clinical safety profile, these changes in exposure for VEL are not deemed clinically significant.

During this procedure, the applicant proposed an update to the dosing regimen to allow administration of the SOF/VEL400/100mg tablet to children weighing ≥ 30kg instead of the previously proposed ≥ 35 kg weight cut off. The simulations for the new proposed weight cut-off show that administration of the 400/100mg dose to children weighing &gt;30 kg will decrease the percentage of children in the weight band of 30 to 40 kg with Ctau values below the 5th percentile of adults from 12% to 4% for VEL. Since dosing in the paediatric study was based on age rather than weight, low weight subjects in group 1 achieved high exposures, and high weight subjects in group 2 quite low exposures. The high exposures seen in children at low weight subjects did not seem to be associated with any specific safety concerns in this study. Overall, the slightly higher exposures expected with regards to this change of weigh cut off from ≥ 30kg instead of ≥ 35 kg, are considered unlikely to have a relevant impact on the safety profile, having in mind the wide therapeutic index for sofosbuvir and velpatasvir. To simplify the safety follow-up, a specific subsection on AEs reported for the paediatric population will be presented in coming PSURs, with adequate narratives to allow for a proper assessment.

## 2.4.4. Conclusions on clinical pharmacology

Overall, the population PK analysis provides an adequate description of sofosbuvir and velpatasvir exposure in children 6-18 years of age. Given the range of weight bands studied and no data on posology in patients below 17 kg, the CHMP considered that the product use should be limited to patients aged 6 years and older and weighing at least 17 kg.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Main study

The present application is based on the results of an ongoing study GS-US-342-1143, a phase 2, open-label, multicentre, multi cohort study to investigate the safety and efficacy of sofosbuvir/velpatasvir in adolescents and children with chronic HCV infection. The study is evaluating SOF/VEL in children aged 3 to &lt;17 years old, the data presented with this application pertain to ages 12 to &lt;17 (group 1) and 6 to &lt;12 (group 2).

## 2.5.1.1. Methods

## · Study participants

## Main inclusion criteria

- Parent or legal guardian was able to provide written informed consent prior to any screening evaluations
- Chronic HCV infection (≥ 6 months) as documented by prior medical history or liver biopsy, with HCV RNA ≥ 1000 IU/mL at screening
- Treatment naive to an approved or experimental DAA based regimen; prior IFN-based theray with or without an HCV protease inhibitor was allowed)

## Main exclusion criteria

- Current or prior history of clinical hepatic decompensation
- The following laboratory parameters at screening:
- a) International normalized ratio (INR) &gt; 1.2 × upper limit of normal (ULN)
- b) Platelets &lt; 50,000/mm3
- c) Albumin &lt; 3.5 g/dL
- d) Alanine aminotransferase (ALT)&gt; 10 × ULN
- e) Aspartate aminotransferase (AST) &gt; 10 × ULN
- f) Direct bilirubin &gt; 1.5 × ULN
- g) eGFR &lt;90 mL/min/1.73m2, as calculated by the SchwartzFormula
- Chronic liver disease of a non-HCV etiology
- Coinfection with HIV or HBV co-infection
- Substantial psychiatric illness
- Clinically relevant alcohol or drug abuse within 12 months of screening.

## · Treatments

Group 1 (12-&lt;17 years): SOF/VEL 400/100 mg qd, taken as one 400/100 FDC tablet or as two 200/50 mg FDC tablets.  The selection of tablet strength was based on a swallowability assessment using matching placebo tablets prior to start of therapy, where 92/102 were able to swallow the adult size tablet, and the other 11 were able to swallow the 200/50 mg tablet.

Both tablets are film-coated; the adult tablet is diamond shaped of dimensions 20 x 10 mm, the 200/50 mg tablet is oval-shaped and 14 x 7 mm.

<div style=\"page-break-after: always\"></div>

Group 2 (6-&lt;12 years): SOF/VEL 200/50 mg qd, taken as one 200/50 mg FDC tablet, or as oral granule formulation (4 x 50/12.5-mg packets). The children completed a swallowability assessment at screening up to Day 1 using placebo tablets, to determine which formulation to choose; 71/73 subjects were treated with tablets, 2 with the oral granule formulation.

## Disposition

All enrolled subjects that received at least 1 dose of study drug and were included in both the Safety Analysis Set and FAS. All but 1 subject of the enrolled subjects completed study treatment, this 1 subject prematurely discontinued study treatment due to pregnancy, table x below.

Table 8 Subject disposition

| Subject Disposition                  | Group 1 12-<17 SOF/VEL (400/100 mg)   | Group 2 6-<12 SOF/VEL (200/50mg)   |
|--------------------------------------|---------------------------------------|------------------------------------|
| Screened                             | 103                                   | 73                                 |
| Not Enrolled                         | 1                                     | 0                                  |
| Enrolled                             | 102                                   | 73                                 |
| Enrolled Never Treated               | 0                                     | 0                                  |
| Safety Analysis Set                  | 102                                   | 73                                 |
| FAS                                  | 102                                   | 73                                 |
| Lead-in Phase PK Analysis Set        | 17                                    | 20                                 |
| Completed Study Treatment            | 101 (99%)                             | 69 (95%)                           |
| No FU-4 HCV RNA Assessment           | 3                                     | 1                                  |
| With FU-4 but no FU-12 HCV RNA       | 1                                     | 2                                  |
| Discontinued Study Treatment         | 1                                     | 4 (5%)                             |
| No FU-4 HCV RNA Assessment           | 0                                     | 2                                  |
| With FU-4 but no FU-12 HCV RNA       | 0                                     | 0                                  |
| Reason for Premature Discontinuation |                                       |                                    |
| Pregnancy                            | 1                                     |                                    |
| AE                                   |                                       | 2                                  |
| Investigator´s discretion            |                                       | 1                                  |
| Lack of efficacy                     |                                       | 1                                  |

In group 1 (12-18 years old), all but 1/102 treated subjects completed the study regimen. In group 2 (6-12 years old) 4/73 subjects discontinued treatment, two of whom due to adverse events,

Baseline characteristics are summarised in the table 11 below. The gender mix is quite even in both groups. The majority had normal transaminases at baseline. The study subjects had very mild HCV-infection; HCV-infection has a mild course in the paediatric ages in the vast majority of cases.

<div style=\"page-break-after: always\"></div>

## Table 9 Baseline characteristics

| Characteristic                   | Characteristic                      | Group 1 SOF/VEL FDC (400/100 mg) (102)   | Group 2 SOF/VEL FDC (200/50 mg) (73)   |
|----------------------------------|-------------------------------------|------------------------------------------|----------------------------------------|
| Age at Baseline (Years)          | Age at Baseline (Years)             |                                          |                                        |
|                                  | Mean (SD)                           | 15 (1.9)                                 | 8 (1.6)                                |
|                                  | Median                              | 15                                       | 8                                      |
|                                  | Q1, Q3                              | 13, 17                                   | 7, 9                                   |
|                                  | Min, Max                            | 12, 17                                   | 6, 11                                  |
| Male gender                      | Male gender                         | 50 (49%)                                 | 35 (48%)                               |
| Race                             | White                               | 74 (72%)                                 | 66 (90%)                               |
|                                  | Asian                               | 11 (11%)                                 | 1 (1.4%)                               |
|                                  | Black or African American           | 9 (8.8%)                                 | 4 (5.5%)                               |
|                                  | Other                               | 5 (4.9%)                                 | 2 (2.7%)                               |
|                                  | American Indian or Alaska Native    | 2 (2.0%)                                 | 0                                      |
|                                  | Not Disclosed                       | 1 (1.0%)                                 | 0                                      |
|                                  | Native Hawaiian or Pacific Islander | 0                                        | 0                                      |
| Weight                           | Mean (kg)                           | 60.6                                     | 29.7                                   |
|                                  | Median                              | 56.9                                     | 26.7                                   |
|                                  | Q1, Q3                              | 47.5, 67.0                               | 23.0, 35.0                             |
|                                  | Min, Max                            | 21.5, 146.5                              | 18.4, 77.9                             |
| Cirrhosis                        | Cirrhosis                           |                                          |                                        |
| Yes                              |                                     | 0                                        | 0                                      |
| No                               |                                     | 40 (39.2%)                               | 31 (42.5%)                             |
| Not Determined                   | Not Determined                      | 62 (60.8%)                               | 42 (57.5%)                             |
| Baseline ALT Category≤ 1.5 x ULN | Baseline ALT Category≤ 1.5 x ULN    | (80.4%)                                  | 47 (64.4%)                             |
| Treatment-Experienced            | Treatment-Experienced               | 22/102 (21.6%)                           | 4/73 (5.5%)                            |

Table 10 Table x Baseline weight

| Baseline Weight (kg) Group 1, 12<17 years (400/100 mg, adult dose)   | Baseline Weight (kg) Group 1, 12<17 years (400/100 mg, adult dose)   | Baseline Weight (kg) Group 1, 12<17 years (400/100 mg, adult dose)   |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| 25 subjects in interval                                              | 21-47 kg                                                             | 25 subjects aged 12-13                                               |
| 25                                                                   | 47-57 kg                                                             | 25 subjects aged 13-15                                               |
| 25                                                                   | 57-67 kg                                                             | 50 subjects aged 15-17                                               |
| 25                                                                   | 67-147 kg                                                            |                                                                      |

<div style=\"page-break-after: always\"></div>

| Baseline Weight (kg) Group 2, 6-<12 years given tablet 200/50 mg   | Baseline Weight (kg) Group 2, 6-<12 years given tablet 200/50 mg   | Baseline Weight (kg) Group 2, 6-<12 years given tablet 200/50 mg   |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
| 17 subjects in interval                                            | 18-23 kilo                                                         | 17 subjects aged 6-7                                               |
| 17                                                                 | 23-27 kilo                                                         | 17 subjects aged 7-8                                               |
| 17                                                                 | 27-35 kilo                                                         | 17 subjects aged 8-9                                               |
| 17                                                                 | 35-78 kilo                                                         | 17 subjects aged 9-11                                              |

## 2.5.1.2. Results

Two subjects in group 2 did not take tablets but were treated with the granule formulation. The efficacy evaluation therefore concerns 71/73 in group 2. The SVR12 rate is high, in line with that seen in the adult population.

Table 11 Efficacy outcomes

|                                | Group 1 12-<17 years 400/100 mg (N = 102)   | Group 2 6-<12 years 200/50 mg (FDC tablet) (N=71)   |
|--------------------------------|---------------------------------------------|-----------------------------------------------------|
| SVR12                          | 97/102 (95.1%)                              | 66/71 (93.0%)                                       |
| Overall Virologic Failure      | 1/102                                       | 1/71 (1.4%)                                         |
| Relapse                        | 1/102                                       | 0/69                                                |
| Completed Study Treatment      | 0/101                                       | -                                                   |
| Discontinued Study Treatment   | 1/1                                         | -                                                   |
| On-Treatment Virologic Failure | 0/102                                       | 1/71 (1.4%)                                         |
| Other                          | 4/102 (3.9%)                                | 4/71 (5.6%)                                         |

Group 1: 5/102 patients did not achieve SVR12. 1 subject relapsed, she stopped treatment at day 29 due to pregnancy. 4 subjects were categorized as 'Other'. 3 subjects were 'lost to follow-up'. All 3 completed therapy, had rapid viral responses and were negative at EOT, but did not come back for the planned followup visits EOT. 1 subject (TE) was pending a posttreatment Week 12 visit at the time of analysis.

Group 2: 5/71 subjects did not achieve SVR12. 1 had 'non-response' (10 year-old white female). Although compliance was 100% according to pill count, viral load over time indicating low adherence (including stop of therapy for a period from week 1 to week 4). 4 subjects were categorized as 'other'. As for group 1, 3 were 'lost to follow-up': all 3 completed therapy, with rapid adequate response to treatment. One did not return after EOT, 2 had SVR4 and did not return for the 3 months follow-up. The fourth subject did not return after the BL visit.

## 2.5.2. Discussion on clinical efficacy

While the study treatments (dosing) were based on age, the dosing schedule that is proposed as part of the application, is based on weight, which is considered a more adequate parameter. This is supported by the weight baseline data in the in the two age groups. Of note, at least some subjects in group 2 (200/50 mg qd) had a baseline weight where the adult dose (400/100 mg) would appear more adequate. However, the study

<div style=\"page-break-after: always\"></div>

data showed no true virological failures. Conversely, some subjects in group 1, with a low weight, were given the adult dose. However, the safety data in the study were re-assuring and did not raise any concerns.

In summary, although it is apparent that dosing by weight is more reasonable, the overall data confirm the wide therapeutic index of the drugs, both efficacy and safety wise.

The SVR12 rate in adolescents (dosed 400/100 mg) and children 6- &lt;12 (dosed 200/50 mg) was around 95%, fully in line with results obtained in adults, despite the fact that a proportion of the younger group (with a higher weight for their age) achieved a lower dose.

The children studied had mild disease characteristics; however, this is considered typical of the paediatric population. Different HCV subtypes were represented, which the CHMP considered reassuring.

## 2.5.3. Conclusions on the clinical efficacy

The CHMP concluded that SOF/VEL is effective in the treatment of chronic HCV in children aged 6 years and older and weighing at least 17 kg.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

## 2.6.1. Patient exposure

## Subjects 12 to &lt; 18 Years

The mean (SD) duration of exposure to SOF/VEL for subjects 12 to &lt; 18 years old in Group 1 was 12.0 (0.80) weeks, and 99.0% of subjects (101 of 102) received SOF/VEL for 12 weeks.

## Subjects 6 to &lt; 12 Years

The mean (SD) duration of exposure to SOF/VEL for subjects 6 to &lt; 12 years old in Group 2 was 11.7 (1.90) weeks, and 94.5% of subjects (69 of 73) received SOF/VEL for 12 weeks.

## 2.6.2. Adverse events

Treatment was to be well tolerated, and severe AEs distinctly uncommon.  In group 1, 1 subject experienced Grade 3 suicidal ideation, and 1 experienced Grade 3 suicidal ideation and worsening of bipolar disorder II and Grade 4 suicide attempt; these AEs were assessed as not related. In group 2, the grade 3 AE concerns a case with auditory hallucinations, judged as related to treatment by the investigator.

Table 12 Number (%) of subjects experiencing AEs

| Number (%) of Subjects Experiencing       | Group 1 12-<17 (102)   | Group 2 6-<12 (73)   |
|-------------------------------------------|------------------------|----------------------|
| Any Adverse Event                         | 77 (75.5%)             | 59 (80.8%)           |
| Grade 3                                   | 1 (1%)                 | 1 (1.4%)             |
| Grade 4                                   | 1 (1%)                 | 0                    |
| Treatment-Related AE                      | 41 (40.2%)             | 25 (34.2%)           |
| Grade ≥3 Treatment -Related Adverse Event | 0                      | 1 (1.4%)             |
| Serious AE                                | 2 (2.0%)               | 2 (2.7%)             |
| Treatment-Related                         | 0                      | 1 (1.4%)             |
| AE Leading to stopping therapy            | 0                      | 2 (2.7%)             |
| AE Leading to interruption                | 0                      | 3 (4.1%)             |
| All Deaths                                | 0                      | 0                    |

Table 13 Adverse Events Reported for ≥ 5% of Subjects

| Group 1 (400/100 mg) 12-<17 (N = 102)   | Group 1 (400/100 mg) 12-<17 (N = 102)   | Group 2 (200/50 mg) 6-<12 (N = 73)   | Group 2 (200/50 mg) 6-<12 (N = 73)   |
|-----------------------------------------|-----------------------------------------|--------------------------------------|--------------------------------------|
| Event                                   | frequency                               | Event                                | frequency                            |
| Any Adverse Event                       | 77 (75.5%)                              | Any Adverse Event                    | 59 (80.8%)                           |
| Headache                                | 30 (29.4%)                              | Vomiting                             | 12 (16.4%)                           |
| Fatigue                                 | 22 (21.6%)                              | Cough                                | 11 (15.1%)                           |
| Nausea                                  | 17 (16.7%)                              | Headache                             | 11 (15.1%)                           |

<div style=\"page-break-after: always\"></div>

| Abdominal pain upper   | 10 (9.8%)   | Abdominal pain   | 9 (12.3%)   |
|------------------------|-------------|------------------|-------------|
| Pyrexia                | 10 (9.8%)   | Fatigue          | 9 (12.3%)   |
| Cough                  | 9 (8.8%)    | Pyrexia          | 8 (11.0%)   |
| Dizziness              | 9 (8.8%)    | Nasopharyngitis  | 7 (9.6%)    |
| Oropharyngeal pain     | 9 (8.8%)    | Rash             | 7 (9.6%)    |
| Vomiting               | 9 (8.8%)    | Upper RTI        | 7 (9.6%)    |
| Diarrhoea              | 7 (6.9%)    | Diarrhoea        | 6 (8.2%)    |
| Abdominal pain         | 6 (5.9%)    | Epistaxis        | 6 (8.2%)    |
| Nasal congestion       | 6 (5.9%)    | Nausea           | 5 (6.8%)    |
| Nasopharyngitis        | 6 (5.9%)    | Arthralgia       | 4 (5.5%)    |
|                        |             | Nasal congestion | 4 (5.5%)    |
|                        |             | Rhinorrhoea      | 4 (5.5%)    |

Table 14 Treatment-Related Adverse Events Reported for &gt; 1 subject

| Group 1 12-<17 (N = 102)   | Group 1 12-<17 (N = 102)   | Group 2 6-<12 (N = 73)   | Group 2 6-<12 (N = 73)   |
|----------------------------|----------------------------|--------------------------|--------------------------|
| Event                      | frequency                  | Event                    | frequency                |
| Any Treatment-Related AE   | 41 (40.2%)                 | Any Treatment-Related AE | 25 (34.2%)               |
| Headache                   | 18 (17.6%)                 | Fatigue                  | 8 (11.0%)                |
| Fatigue                    | 16 (15.7%)                 | Headache                 | 5 (6.8%)                 |
| Nausea                     | 15 (14.7%)                 | Abdominal pain           | 3 (4.1%)                 |
| Dizziness                  | 5 (4.9%)                   | Abdominal pain upper     | 3 (4.1%)                 |
| Abdominal pain             | 4 (3.9%)                   | Diarrhoea                | 3 (4.1%)                 |
| Abdominal pain upper       | 4 (3.9%)                   | Irritability             | 2 (2.7%)                 |
| Diarrhoea                  | 2 (2.0%)                   | Product use issue        | 2 (2.7%)                 |

## 2.6.3. Serious adverse event/deaths/other significant events

There were two cases of SAEs in group 1, both considered treatment unrelated. One subject, with attention deficit/hyperactivity disorder (treated with lisdexamfetamine, Vyvanse) experienced a Grade 3 SAE of suicidal ideation, assessed as not related to study drug on Day 55, which resolved on Day 57 without interruption of study drug. One patient had an ongoing Grade 3 SAE of exacerbated bipolar disorder II on Day 1 of the study and a Grade 3 SAE of suicidal ideation on Day 69 of the study, which resolved 12 days later on Day 80. On Day 75, the subject had a Grade 4 SAE of suicide attempt. The SAEs were assessed as not related to study drug and there was no interruption of the study drug. Medical history of ongoing bipolar disorder II, frequent suicidal thoughts, anorexia, bulimia, emotional abuse, attention deficit hyperactivity disorder, and oral and receptive language disorders, and a prior history of suicidal ideation, suicide attempt, and sexual abuse.

There were two cases of SAEs in group 2. One subject with a medical history of ongoing chronic constipation experienced a Grade 2 SAE of constipation on Day 3, which was assessed as not related to study drug. Resolved day 5, after in-ward treatment. The SAE was considered treatment unrelated. One subject with a medical history of asthma, seasonal allergies, allergic shiners experienced 'negative thoughts' (grade 2) and a grade 3 SAE of 'auditory hallucinations', assessed as related to study drug by the investigator.

<div style=\"page-break-after: always\"></div>

## AEs and drug levels

Sofosbuvir levels in the paediatric patients in study GS-US-342-1143 are well covered by levels seen in patients with severe renal impairment, studied without particular safety issues. The main metabolite is not higher in the paediatric population than in adults with normal renal function.

Velpatasvir levels are higher in the lower age spans in group 1 and 2 as compared to levels seen in the adult population. These levels are not increased in the adult special populations (neither in those with severe renal impairment (not studied at large), nor in those with severely impaired liver function (studied at large), i.e. 'not covered' by adult safety data.

Summary statistics of SOF and VEL exposure parameters by the presence or absence of common AEs by age groups are shown in Figure 12, Figure 13, Figure 14 and Figure 15 below (SOF for group 1 and 2, followed by VEL for group 1 and 2, respectively). No relevant differences in exposures by presence or absence of the common AEs (headache, fatigue, nausea, vomiting or cough) are seen.

Figure 12 Summary statistics of SOF exposure by the presences of common AEs (group 1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13 Summary statistics of SOF exposure by the presences of common AEs (group 2)

<!-- image -->

Figure 14 Summary statistics of VEL exposure by the presences of common AEs (group 1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 15 Summary statistics of VEL exposure by the presences of common AEs (group 2)

<!-- image -->

## Psychiatric AEs and drug levels

Considering the more severe psychiatric events reported in a small number of subjects, details for subjects with reported Psychiatric Disorders are summarized in Table 16 and Table 17 below. With the exception of the cases already discussed, events are of grade 1, with a scattered pattern of terms, and without any indication for a disproportional proportion with markedly high VEL exposures.

Table 15 Subjects in group 1 (12-17 years) with AE reports of psychiatric disorders

| age/gen der   | Problem                                     | grade   | Related/not related   | days   | AUC tau (1)   |   AUC TAU (2) |
|---------------|---------------------------------------------|---------|-----------------------|--------|---------------|---------------|
| 14/M          | Sleep disorder                              | 1       | NR                    | ?-63   | -             |          2803 |
| 14/M          | Sleep disorders                             | 1       | related               | 76-83  | -             |          4838 |
| 13/F          | Suicidal ideation (narrative previous page) | 3       | NR                    | 55-57  | -             |          4304 |
| 12/F          | Emotional sensitivity                       | 1       | related               | 26-41  | -             |          1396 |
| 13/M          | ADHD                                        | 1       | NR                    | 44-    | -             |          3228 |
| 14/F          | Selective eating disorder                   | 1       | NR                    | 29-    | -             |          3435 |
| 17/F          | Irritability                                | 1       | related               | 1-28   | -             |          4725 |
| 15/F          | Hearing voices                              | 1       | NR                    | ?      | -             |          1552 |
| 14/F          | Narratives previous page                    | 2/3     |                       |        | 3237.0        |          3237 |

Also in group 2 psychiatric AEs were fairly infrequent, predominantly of grade 1.

<div style=\"page-break-after: always\"></div>

Table 16 Details on all subjects in group 2 (6- &lt;12 years) with AE reports of psychiatric disorder

| age/ gender   | Problem                        | grade   | Related/not related   | days   | AUC tau (1)   |   AUC TAU (2) |
|---------------|--------------------------------|---------|-----------------------|--------|---------------|---------------|
| 8/M           | worsening ADHD                 | grade 2 | NR                    | 29-    | 2603.2        |          2569 |
| 8/F           | sleep disturbance              | grade 1 | related               | 19-22  | -             |          1181 |
| 8/F           | Dizzy                          |         | related               | 49-57  | -             |          1181 |
| 6/M           | sleep walking                  | grade 1 | NR                    | 51-51  | -             |          4202 |
| 8/M           | worsening oppositional defiant | grade 1 | related               | 4-6    | -             |          2757 |
| 7/F           | Irritability                   | grade 1 | related               | 6-     | 2436.6        |          4195 |
| 11/F          | worsening anxiety              | grade 1 | NR                    | 18-    | -             |          1413 |
| 8/F           | increased emotions             | grade 1 | related               | 18-57  | 3135.2        |          3389 |
| 6/F           | increased fear of being alone  | grade 1 | NR                    | ?      | -             |          4407 |
| 8/M           | irritability                   | grade 1 | related               | 3-28   | -             |          5531 |
| 6/F           | unpleasant thoughts            | grade 2 | related               |        | 7343.4        |          5743 |
| 6/F           | auditory hallucinations        | grade 3 | related               |        | 7343.4        |          5743 |

## 2.6.4. Laboratory findings

When looking at maximum graded toxicity below, it should be noted that no clinically meaningful changes from baseline in hemoglobin, reticulocytes, neutrophils, lymphocytes, or platelets were observed for subjects 12 to &lt; 18 years old (Table 18). The grade 3 Hemoglobin concerns a subject with thalassemia, the grade 3 neutrophils concern subjects with low neutrophils at baseline, grade 3 CK followed heavy exercise and grade 3 glucose a subject with diabetes.

Similarly, no clinically meaningful changes from baseline in hemoglobin, reticulocytes, neutrophils, lymphocytes, or platelets were observed for subjects 6 to &lt; 12 years old, and no grade 3 or 4 max lab toxicity was seen in this group.

Table 17 Laboratory findings by toxicity grade

| Parameter                        | Group 1 12-<18   | Group 2 6-<12   |
|----------------------------------|------------------|-----------------|
| Maximum Post dose Toxicity Grade | 102              | 71              |
| Grade 1                          | 35 (34%)         | 24 (34%)        |
| Grade 2                          | 4 (4%)           | 3 (4%)          |
| Grade 3                          | 5 (5%)           | 0               |
| Grade 4                          | 0                | 0               |
| Hemoglobin                       | 102              | 71              |
| Grade 1                          | 4                | 1               |
| Grade 2                          | 1                | 0               |
| Grade 3                          | 1                | 0               |
| Grade 4                          | 0                | 0               |
| Lymphocytes                      | 70               | Not provided    |
| Grade 1                          | 0                |                 |
| Grade 2                          | 0                |                 |
| Grade 3                          | 0                |                 |
| Grade 4                          | 0                |                 |
| Neutrophils                      | 102              | 71              |
| Grade 1                          | 2                | 4 (6%)          |
| Grade 2                          | 2                | 0               |
| Grade 3                          | 2                | 0               |

<div style=\"page-break-after: always\"></div>

| Grade 4                 | 0     | 0     |
|-------------------------|-------|-------|
| Platelets               | 102   | 71    |
| Grade 1                 | 2     | 0     |
| Grade 2                 | 1     | 0     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| ALT                     | 102   | 71    |
| Grade 1                 | 1     | 0     |
| Grade 2                 | 0     | 1     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| ALP                     | 102   | 71    |
| Grade 1                 | 1     | 0     |
| Grade 2                 | 0     | 0     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| GGT                     | 102   | 71    |
| Grade 1                 | 0     | 1     |
| Grade 2                 | 0     | 0     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| BIL (total)             | 102   | 71    |
| Grade 1                 | 3     | 0     |
| Grade 2                 | 0     | 0     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| CK                      | 102   | 71    |
| Grade 1                 | 1     | 0     |
| Grade 2                 | 0     | 0     |
| Grade 3                 | 1     | 0     |
| Grade 4                 | 0     | 0     |
| Creatinine              | 102   | 71    |
| Grade 1                 | 0     | 0     |
| Grade 2                 | 0     | 0     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| Lipase                  | 102   | 71    |
| Grade 1                 | 3     | 1     |
| Grade 2                 | 0     | 1     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |
| Glucose (Hyperglycemia) | 102   | 71    |
| Grade 1                 | (14%) | (11%) |
| Grade 2                 | 2     | 1     |
| Grade 3                 | 1     | 0     |
| Grade 4                 | 0     | 0     |
| Glucose (Hypoglycemia)  | 102   | 71    |
| Grade 1                 | 7     | 2     |
| Grade 3                 | 0     | 0     |
| Grade 4                 | 0     | 0     |

## Discontinuation due to adverse events

No adolescent subjects (group 1) discontinued or interrupted therapy due to AEs. Two subjects in group 2 discontinued due to AEs: one refused to take the treatment and the other case concerned the subject with auditory hallucinations, discussed above.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Discussion on clinical safety

SOF/VEL therapy was well tolerated in study GS-US-342-1143, despite the study design (dosing by age) which led to quite high exposures in some subjects (e.g. low weight for age, dosed 400/100 mg). Grade 3 or 4 AEs were very uncommon and only in one case (grade 3) considered related to therapy. Laboratory tests did not reveal any issues of concern.

In the 173 treated with the tablet formulation, serious adverse events were reported in 4 patients.

In age group 12-17 (n= 102) there were 1 case of suicidal ideation, not considered related to treatment by the investigator, which was endorsed by the CHMP, as there were alternative causes for the event. The other event concerned suicidal ideation and a suicide attempt. The investigator assessed these events as potentially triggered by starting hep C therapy and being part of the study, but not to the treatment per se. That conclusion was endorsed by the CHMP. In age group 6- &lt;12 (n= 71 plus), an event of 'negative thoughts (grade 2), followed by 'auditory hallucinations' was reported in one patient, but the CHMP concluded that there was not sufficient evidence to conclude on a causal relationship. Update of the Product Information was not deemed necessary at this point.

With regards to psychiatric AEs overall, terms other than 'headache' are uncommon, and with no distinct pattern.

## 2.6.6. Conclusions on the clinical safety

The safety assessment of Epclusa in paediatric patients aged 6 years and older is based on data from a phase 2, open-label clinical study that enrolled patients who were treated with sofosbuvir/velpatasvir for 12 weeks. The adverse reactions observed were consistent with those observed in clinical studies of Epclusa in adults.

The CHMP recommended that future PSURs of Epclusa should include a specific subsection on AEs reported in the paediatric population, with adequate narratives to allow for a meaningful assessment.

## 2.7. Risk Management Plan

## Safety concerns

## Summary of safety concerns

A new version of the RMP (version 6, dated 19 June 2020) was submitted as part of this application. The summary of safety concerns, below, is unchanged as compared to previous version and this is endorsed.

## Summary of Safety Concerns

| Important Identified Risks   | Severe bradycardia and heart block when used with concomitant amiodarone HBV reactivation in HBV/HCV coinfected patients   |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Important Potential          | Recurrence of HCC                                                                                                          |

## Missing Information

Safety in pregnant women

Development of resistance

Safety in patients with previous HCC

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

The MAH has updated the study title and milestones for HCC emergence post-authorisation safety study (PASS). In addition, the date of 'submission of updated joint protocol' regarding De Novo DAA PASS was amended from 29 March 2019 (date of version 3 of the protocol) to 02 April 2019 (date of submission), in Table 2 1. Ongoing and Planned Additional Pharmacovigilance Activities and Table 3 1. Ongoing and Planned Additional Pharmacovigilance Activities.

The proposed changes are endorsed.

Summary table of additional pharmacovigilance activities:

<div style=\"page-break-after: always\"></div>

Table 3-1. Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                              | Summary of Objectives                                                                                                                                                                                                                                         | Safety Concerns Addressed                                                                                                                                                                                                 | Milestones                                                                                                                                                                                                                | Due dates                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category l - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                | Category l - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                    | Category l - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                | Category l - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                | Category l - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                |
| DAA-PASS: A post-authorisation safety study of early recurence of hepatocellular carcinoma in HCV-infected patients after direct-acting antiviral therapy                                                                 | To evaluate the impact of DAA. treatment on the incidence ofHCC recuwrence, relative to no DAA therapy                                                                                                                                                        | Importort potential risk: Recurence of HCC Missing information: Safety in patients with previous HCC                                                                                                                      | Submission of interim and final reports                                                                                                                                                                                   | Interim Apnps report Q3 2021 Final study Q2 2023                                                                                                                                                                          |
| Category 2  Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2  Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                     | Category 2  Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2  Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2  Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                                                      | None                                                                                                                                                                                                                                                          | None                                                                                                                                                                                                                      | None                                                                                                                                                                                                                      | None                                                                                                                                                                                                                      |
| GS-US-248-0123 A Long Tem Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic                                                       | To evaluate HCV viral sequences and the persistence or evolution of treatment-emergent viral mutations in subjects who fail to achieve an SVR after treatment with a Gilead oral antiviral containing regimen im a previous Gilead-sponsored hepatitis C Aprs | Missing informatfion: Development of resistance                                                                                                                                                                           | Submission of podar eug                                                                                                                                                                                                   | Final Aprs July 2020                                                                                                                                                                                                      |
| De Novo DAA PASS: A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated                                                                                                           | To evaluate among compensated cirrhotic patients, whether DAA therapy for chronic HCV incident HCC compared to no treatment or treatment                                                                                                                      | Importort potential risk: Emergence of HCC                                                                                                                                                                                | Submission of updated joint protocol                                                                                                                                                                                      | 02 April 2019                                                                                                                                                                                                             |
| cirrhosis treated                                                                                                                                                                                                         | infection increases the risk of with IFN-based regimens                                                                                                                                                                                                       |                                                                                                                                                                                                                           | End of Data Collection                                                                                                                                                                                                    | 18 months after protocol [BAOIdde by IRB and PRAC                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

The MAH has updated the study title for HCC emergence PASS for the important potential risk 'Emergence of HCC', in line with changes made in Part III of the RMP. The Part VI, Annex 2 (Tabulation Summary of Planned, Ongoing, and Completed Pharmacovigilance Study Program) and Annex 3 (Protocols for Proposed, Ongoing and Completed Studies in the Pharmacovigilance Plan) were updated accordingly, in line with the updated Part III of the RMP.

Two minor improvements were also made in the RMP, addressing the following minor updates which were being requested for consistency purposes only:

- In Table 1 1 Planned and Ongoing Studies of Annex 2, the date of 'submission of updated joint protocol' regarding De Novo DAA PASS was amended from 29 March 2019 (date of version 3 of the protocol) to 02 April 2019 (date of submission);

- In Annex 8 - Summary of changes to the risk management plan over time, the MAH has added the procedure number 'EMEA/H/C/004210/X/0043/G' in the column 'Approval date procedure' and the sentence 'No changes to safety concerns.' at the end of the subsection 'Safety specification' of the column 'Changes' of the update of the RMP (version 5.1).

This is endorsed.

## Summary table of Pharmacovigilance and Risk Minimisation Activities by Safety Concern

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                           | RiskMinimization Measures                                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risk(s)                                             |                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                        |
| Severe bradycardia and heart block when used with concomitant amiodarone | Routine risk minimization measures: SmPC section 4.4, 4.5, and 4.8 PL section 2. Additional risk minimization measures: None                                                                                                                                                | Routine phammacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire for bradyarrhythmia Additional phammacovigilance activities: None                                                                       |
| HBV reactivation in HBV/HCV coinfected patients                          | Routine risk minimization measures: SmPC Section 4.4 PL Section 2 Additional risk minimization measures: None                                                                                                                                                               | Routine phamacovigilance activities beyond adverse reactions reporting and signal detection: None Additional phanmacovigilance activities: None                                                                                                                        |
| Important potential risk(s)                                              |                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                        |
| Recurence of HCC                                                         | Routine risk minimization measures: None Additional risk minimization measures: None The need for risk minimization measures will be reassessed following the availability of the results from a study for HCC recurence.                                                   | Routine phammacovigilance activities beyond adverse reactions reporting and signal detection: None Additional phammacovigilance activities: Study to assess the impact of DAA treatment on the incidence of HCC recuwrence, relative to no DAA therapy                 |
| Emergence of HCC                                                         | Routine risk minimization measures: None Additional risk minimization measures: None The need for risk minimization measures will be reassessed following the availability of results from a study of the impact of DAA therapies on the incidence and type of de novo HCC. | Routine phammacovigilance activities beyond adverse reactions reporting and signal detection: None Additional phammacovigilance activities: Study to evaluate the risk of de novo HCC in patients with compensated cirrhosis treated with DAAs for chronic hepatitis C |

<div style=\"page-break-after: always\"></div>

| Safety Concern                       | RiskMinimization Measures                                                                                                                                                                                                                                                                    | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                          |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information                  |                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                       |
| Safety in pregnant women             | Routine risk minimization measures SmPC section 4.6 PL section 2. Additional risk minimization measures: None                                                                                                                                                                                | Routine phammacovigilance activities beyond adverse reactions reporting and signal detection: Additional phammacovigilance activities: None                                                                                                                                                                                           |
| Development of resistance            | Routine risk minimization measures: None Additional risk minimization measures: None No risk minimization measures are considered necessary for the development of resistance at this time. Clinical data suggest that the presence of an NS5A RAV does not preclude successful retreatment. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional phammacovigilance activities: Long term follow-up registy study of subjects who did not achieve sustained virologic response im Gilead-sponsored trials in subjects with chronic hepatitis C infection (GS-US-248-0123) |
| Safety in patients with previous HCC | Routine risk minimization measures: None Additional risk minimization measures: None The need for risk minimization measures will be reassessed following the availability of the results from a study for HCC recwrence.                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional phammacovigilance activities: Study to assess the impact of DAA treatment on the incidence of HCC recurence, relative to no DAA therapy                                                                                 |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 6 is acceptable.

## 2.8. Pharmacovigilance

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.9. Product information

## 2.9.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Epclusa (sofosbuvir / velpatasvir) is included in the additional monitoring list as it had a PASS imposed at the time of authorisation.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Around 70 million individuals worldwide are chronically infected with HCV. Around 3.5 million children aged 1 to 19 years has been estimated to be infected, mainly in low to middle income countries, including Pakistan, Egypt, Nigeria, China, and Russia (in order of decreasing prevalence).

The natural history of chronic HCV infection in children is relatively benign. Most children are asymptomatic or have mild nonspecific symptoms; cirrhosis development within childhood/adolescence is rare but has been reported. In the general case, it takes decades to develop cirrhosis.

The HCV has significant genetic (RNA sequence) variability; 8 major genotypes have been identified: genotypes 1, 3 and 4 are the most prevalent globally.

## 3.1.2. Available therapies and unmet medical need

Highly effective DAA regimens and well tolerated DAA regimens have been available for adults for around 5 years. Some of them have recently been approved for the treatment of adolsecents and children. At present none of the regimens that are available have a pangenotypic effect; Epclusa is indicated for the treatment of HCV regardless of genotype.

## 3.1.3. Main clinical studies

GS-US-342-1143 is an ongoing study, evaluating SOF/VEL is adolescents (group 1), children aged 6 to &lt;12 (group 2) and children aged 3 to &lt;6 (group 3). The present application concerns group 1 and 2, where

<div style=\"page-break-after: always\"></div>

adolescents were given the adult dose (400/100 mg qd) and those aged 6 to &lt;12 half that dose (200/50 mg qd), provided by a new tablet. The treatment duration is the same as in adults, 12 weeks. A granule formulation has been developed for the very small ones (group 3); it was used by two subjects in group 2 who were not able to handle tablets, and those two subjects are not part of the efficacy evaluation.

Of note, since dosing was based on age rather than weight, low weight subjects in group 1 achieved high exposures, and high weight subjects in group 2 quite low exposures.

In line with the expected, the children/adolescents had mild HCV infection (no cirrhotic subjects, when this was evaluated); 80% of subjects in group 1, and two thirds in group 2 had a baseline ALT level &lt; 1.5 x ULN.

## 3.2. Favourable effects

In practice all subjects achieved virological cure; SVR12 was achieved in 97/102 (95%) in group 1, and in 66/71 (93%) in group 2. The majority of those few not achieving SVR12 fulfilled treatment, had an adequate on-treatment response and undetectable HCV-RNA at end of treatment, but failed to come back for the week 12 follow-up visit. There was in practice no non-response or true relapse, despite the fact that some subjects achieved a low dose by weight (above).

## 3.3. Uncertainties and limitations about favourable effects

No uncertainties have been identified about favourable effects.

## 3.4. Unfavourable effects

The treatment was well tolerated. Reported AEs were mainly mild (grade 1 or 2). Grade 3 AEs were reported for 2/175 treated subjects (1 possibly related) and a grade 4 AE was reported for one subject (not deemed related). AEs leading to stopping therapy were reported for two subjects, both in group 2, related to 1) not accepting tablet and 2) a case defined as auditory hallucinations of questionable causality. There was no obvious difference in SOF or VEL exposures in cases with or without the most commonly reported potentially treatment related AEs (headache, fatigue, nausea), despite the fact that a substantial proportion of subjects achieved high exposures as a consequence of dosing by age. In summary, the safety profile in groups 1 and 2 was in line with that reported for adults.

## 3.5. Uncertainties and limitations about unfavourable effects

Adequate population PK analyses of SOF and selected metabolites, and VEL, respectively, has been performed and the models are considered adequate to provide predicted exposure metrics in the paediatric population. There is a slight overprediction of SOF trough concentration in the paediatric subjects, which would result in more conservative estimates of exposures with respect to safety.

Both SOF and VEL has a wide therapeutic index, both from an efficacy and safety perspective.  A pragmatic approach has therefore been chosen on the basis of results obtained in groups 1 and 2 in study GS-US-3421143, where the proposed dosing (200/50 mg qd for weights 17-30, and 400/100 mg (i.e. adult dose) for those above 30 kilo) results in higher exposures of SOF (but not major metabolite) and VEL in children at the lower end of the weight spans than that seen in adults. Having the well described efficacy and safety profiles

<div style=\"page-break-after: always\"></div>

in mind, that is considered acceptable. Given the totality of knowledge on sofosbuvir and velpatasvir, this does not prompt any specific safety concerns.

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

On basis of outcomes and PK in this fairly large paediatric study, and previous results in studies in adults, the proposed dosing schedule is supported. The higher exposures seen in children at low ends of the weight bands is not associated with any specific safety concerns. Of note, higher sofosbuvir exposures have been seen in studies of adults with severe renal insufficiency, for whom SOF/VEL is approved without dose adjustment.

The CHMP considered that there are no data on posology in patients weighing less than 17 kg. This has been reflected in section 4.1 of the SmPC.

## 3.6.2. Balance of benefits and risks

The described similarity of sofosbuvir, GS-331007, and velpatasvir PK in adults and children is considered sufficient to support the efficacy and safety results to the new paediatric population. The efficacy estimate (SVR12) showed a very high cure rate also in the paediatric setting and there were no indications of any agespecific safety concerns.

Given the natural course of chronic HCV infection in comparison to the high cure rate and favourable safety profile of SOF/VEL, the favourable effects outweigh the unfavourable effects.

## 3.7. Conclusions

The overall B/R of Epclusa is favourable.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality and safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Epclusa 200/50 mg film-coated tablets is favourable in the following indication:

- Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 6 years and older and weighing at least 17 kg.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Epclusa subject to the following conditions:

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                           | Due date   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| In order to evaluate the recurrence of hepatocellular carcinoma associated with Epclusa, the MAH shall conduct and submit the results of a prospective safety study using data deriving from a cohort of a well-defined group of patients, based on an agreed protocol. The final study report shall be submitted by: | Q2 2023    |

## Paediatric Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan PIP P/0150/2018 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

In addition, CHMP recommends the variation(s) to the terms of the marketing authorisation, concerning the

<div style=\"page-break-after: always\"></div>

following change(s):

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include paediatric use in patients aged 6 years and older and weighing at least 17 kg. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 6.0) is updated in accordance.

In addition, the MAH took the opportunity to implement minor editorial updates throughout the Product Information.